<SEC-DOCUMENT>0001193125-16-766120.txt : 20161110
<SEC-HEADER>0001193125-16-766120.hdr.sgml : 20161110
<ACCEPTANCE-DATETIME>20161110172556
ACCESSION NUMBER:		0001193125-16-766120
CONFORMED SUBMISSION TYPE:	424B7
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20161110
DATE AS OF CHANGE:		20161110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOVIE MEDICAL Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B7
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-203422
		FILM NUMBER:		161989248

	BUSINESS ADDRESS:	
		STREET 1:		4 MANHATTANVILLE ROAD, SUITE 106
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577
		BUSINESS PHONE:		800-537-2790

	MAIL ADDRESS:	
		STREET 1:		4 MANHATTANVILLE ROAD, SUITE 106
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B7
<SEQUENCE>1
<FILENAME>d282794d424b7.htm
<DESCRIPTION>424B7
<TEXT>
<HTML><HEAD>
<TITLE>424B7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT COLOR="#50748a"><B>Filed pursuant to Rule 424(b)(7) <BR> Registration Statement No.
333-203422 </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Prospectus Supplement
</B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>(To Prospectus dated April 24, 2015) </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B>1,500,000 Shares </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>BOVIE MEDICAL CORPORATION&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g282794g63m68.jpg" ALT="LOGO">
 </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Common Stock </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>$4.00 per share </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #50748a">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="34">&nbsp;</TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">The Selling Stockholders are offering 1,500,000 shares. </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="34">&nbsp;</TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">The last reported sale price for our common stock on November 9, 2016, was $4.67 per share.
</FONT></TD></TR></TABLE></DIV><DIV STYLE="position:relative;float:left; margin-left:2%; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="34">&nbsp;</TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Trading symbol: NYSE MKT &#147;BVX.&#148; </FONT></TD></TR></TABLE></DIV><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.50pt solid #50748a;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B>This investment involves risk. See &#147;<A HREF="#supprom282794_5">Risk Factors</A>&#148; beginning on page S-9. </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:6.00pt solid #50748a">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Per<BR>Share</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Public offering price</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">6,000,000.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Underwriting discount(1)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">360,000.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:6.00pt solid #50748a">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">The selling stockholders have granted the underwriter an option for a period of 30 days to purchase an additional 225,000 shares of our common stock to cover any over-allotments. See
&#147;Underwriting&#148; beginning on page S-22 for additional information regarding total underwriter compensation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Concurrently with the sale of shares of our common stock under this prospectus supplement, Bovie Medical Corporation (the &#147;Company&#148;) is selling 1,500,000 shares of its common stock under another prospectus supplement, as
more fully described herein. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Neither the U.S. Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.50pt solid #50748a;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>Piper Jaffray </B></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>The date of this prospectus supplement is November 10, 2016 </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc"></A>Table of contents </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>Prospectus Supplement </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #50748a"><FONT COLOR="#50748a"><B>Page</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_1">About this prospectus
supplement</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_2">Prospectus supplement summary</A></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_3">The offering</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_4">Cautionary note regarding forward-looking statements
</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_5">Risk factors</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_6">Use of proceeds</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_7">Selling Stockholders</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_8">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_9">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_10">Incorporation of certain information by reference
</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_11">Where you can find additional
information</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_12">Legal matters</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supprom282794_13">Experts</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">S-27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>Prospectus </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_1">PROSPECTUS SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_2">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_4">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_5">SELLING STOCKHOLDERS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_6">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_7">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_8">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_9">WHERE YOU CAN FIND MORE
INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_10">INCORPORATION OF CERTAIN INFORMATION BY
REFERENCE</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-i
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3
(Registration File No. 333-203422) that we filed with the Securities and Exchange Commission (&#147;SEC&#148;) for the resale by the selling stockholders as identified in the &#147;Selling Stockholders&#148; section beginning on page S-19 (the
&#147;Selling Stockholders&#148;) in this prospectus supplement of up to 1,500,000 shares of common stock. Each share of Series B Convertible Preferred Stock is convertible into two shares of common stock. All of the shares, when sold, will be sold
by these Selling Stockholders. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This document is in two parts. The first part is the prospectus supplement, including the
documents incorporated by reference, which describe the specific terms of this offering. The second part, the accompanying prospectus, including the documents incorporated by reference, provides more general information. Generally, when we refer to
this prospectus supplement, we are referring to both parts of this document combined. We urge you to carefully read this prospectus supplement and the accompanying prospectus, and the documents incorporated herein and therein, before buying any of
the securities being offered under this prospectus supplement. This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent that any statement that we make in this prospectus supplement is
inconsistent with statements made in the accompanying prospectus or any documents incorporated by reference therein, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus
and such documents incorporated by reference therein. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">You should rely only on the information contained in or incorporated
by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized for use in connection with this offering. We have not, and the underwriter has not, authorized anyone to provide you
with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the underwriter is not, making an offer to sell these securities in any jurisdiction where the offer or sale is
not permitted. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any free
writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those
dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in
connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement entitled
&#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">No
action is being taken in any jurisdiction outside the United States to permit a public offering of the common stock or possession or distribution of this prospectus supplement or the accompanying prospectus in that jurisdiction. Persons who come
into possession of this prospectus supplement or the accompanying prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this
prospectus supplement or the accompanying prospectus applicable to that jurisdiction. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Concurrently with the sale of shares
of our common stock by the Selling Stockholders under this prospectus supplement, the Company is selling 1,500,000 shares of its common stock under another prospectus supplement, offered pursuant to Registration Statement No.&nbsp;333-193263, or the
2014 Registration Statement, and the prospectus dated December 16, 2014 included therein, or the 2014 Base Prospectus (such offering, the &#147;Concurrent Offering&#148;). As part of the Concurrent Offering, the Company granted the underwriter an
option for a period of thirty (30) days to purchase up to an additional 225,000 shares of our common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As used in this
prospectus supplement, &#147;Bovie,&#148; &#147;we,&#148; &#147;our&#148; &#147;the Company&#148; and &#147;us&#148; refer to Bovie Medical Corporation, unless stated otherwise or the context requires otherwise. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-ii </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_2"></A>PROSPECTUS&nbsp;SUPPLEMENT&nbsp;SUMMARY </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and the
accompanying prospectus. This summary may not contain all the information that you should consider before investing in our common stock. You should read the entire prospectus supplement and the accompanying prospectus carefully, including &#147;Risk
Factors&#148; contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein and the financial statements incorporated by reference in this prospectus supplement and the
accompanying prospectus, before making an investment decision. This prospectus supplement may add to, update or change information in the accompanying prospectus. </I></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our Company </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Bovie Medical Corporation (&#147;Company&#148;, &#147;Bovie Medical&#148;, &#147;we&#148;, &#147;us&#148;, or &#147;our&#148;) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office
at 4 Manhattanville Road, Suite&nbsp;#106, Purchase, New York 10577. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are an energy-based medical device company
specializing in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used in doctor&#146;s offices, surgery centers and hospitals worldwide. Our medical devices are
marketed through Bovie&#146;s own well-respected brands (Bovie<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, IDS&#153; and ICON&#153;) and on a private label basis to distributors throughout the world. The Company also leverages its
expertise in the design, development and manufacturing of electrosurgical equipment by producing equipment for large, well-known medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies
with the need for our energy based designs. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are also the developer of J-Plasma<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>; a patented helium-based plasma surgical product which we believe has the potential to be a transformational product for surgeons.
J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> has FDA clearance for the cutting, coagulation, and ablation of soft tissue. The J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> system consists of an
electrosurgical generator unit (ESU), a hand piece and a supply of helium gas. Radiofrequency (RF) energy is delivered to the hand piece by the ESU and used to energize an electrode. When helium gas is passed over the energized electrode, a helium
plasma is generated which allows for conduction of the RF energy from the electrode to the patient in the form of a precise helium plasma beam. The energy delivered to the patient via the helium plasma beam is very precise and cooler in temperature
in comparison to other surgical energy modalities such as standard RF monopolar energy. While currently in the early stages of commercialization, J-Plasma has been the subject of ten white papers and has been cited therein for its clinical utility
in gynecological and plastic surgery procedures. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Significant Subsidiaries </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Aaron Medical Industries, Inc. is a wholly-owned Florida corporation based in Clearwater, Florida. It is principally engaged in the
business of marketing our medical products.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Bovie Bulgaria, EOOD is a wholly-owned limited liability company incorporated
under Bulgarian law, located in Sofia, Bulgaria. It is engaged in the business of engineering and manufacturing our electrosurgical and OEM products. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Industry </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Healthcare reform has caused consolidation among providers, with hospitals merging, physician practices joining hospitals, and institutions combining to form Accountable Care Organizations, to manage patients on an interdisciplinary
basis. Although the medical device industry can be challenging and very competitive, we believe it will continue to have a positive, long-term growth trajectory with the number of surgical procedures performed increasing annually as a result of the
aging &#147;baby boomer&#148; population and other healthcare trends. </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
Additionally, we also anticipate a continued increase in minimally invasive surgical procedures due to ongoing advancements in technology coupled with continued overall pressure to reduce
healthcare costs via a reduction in patient trauma and recovery time. Expanding global markets will also continue to provide growth opportunities for the medical device industry. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We believe that Bovie Medical has sustainable, competitive advantages in the medical device market for several reasons. We have a long
history in electrosurgery. In fact, our inspiration dates back to the first use of an electrosurgical generator in an operating room in the U.S. in 1926 where Dr. William T.&nbsp;Bovie was present. Thus, the Bovie name is recognized by surgeons the
world over for having pioneered the electrosurgery field and is recognized for its outstanding product quality supported by strong engineering and research and development capabilities. This history equates to very strong recognition of the Bovie
brand. In fact, the word &#147;Bovie&#148; has become synonymous with all instruments used to deliver electrosurgical energy in the operating room. We believe that our equipment and devices have and will continue to provide better experiences for
patients at a lower cost to the healthcare system. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Business Strategy </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our objective is to achieve profitable, sustainable growth by increasing our market share in the advanced energy category, including the
commercialization of products that have the potential to be transformational with respect to the results they produce for surgeons and patients. In order to achieve this objective, we plan to leverage our long history in the industry, along with the
reputation for quality and reliability that the Bovie brand enjoys within the medical community. At the same time, we will expand our products beyond radio frequency, move forward with research and developments projects aimed at creating value
within our existing product portfolio and build our pipeline of new complementary products and utilize multiple channels to bring new and existing products to market. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are working to build our position in advanced electrosurgical generators and disposables, which can be used in diversified niche
markets with minimally invasive surgical instruments, while furthering our status as a pioneer in plasma technology and its various medical applications. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our J-Plasma product initially received FDA clearance in 2012, and a CE mark in December, 2014, which enables us to sell the product in
Europe. In 2014, we brought together a new management team and created and trained a direct sales force dedicated to J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. In 2015, we continued the commercialization process for <FONT
STYLE="white-space:nowrap">J-Plasma</FONT> with a multi-faceted strategy designed to accelerate adoption of the product. This strategy primarily involved deployment of a dedicated sales force, extending and customizing the J-Plasma<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> product line and expanding the surgical specialties in which J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can become the &#147;standard of care&#148; for certain procedures.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As of September 30, 2016, we had a direct sales force consisting of 14 field-based selling positions, and that, coupled with
our independent manufacturer&#146;s representatives, gives us a total sales force of 42. This is a hospital focused selling organization with its focus on the use of J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for operating
room procedures.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Additionally, we launched seven new J-Plasma hand piece configurations and the Bovie Ultimate generator,
which combines J-Plasma functionality with standard electrosurgery modes in one generator. The J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> product line has been recognized by the Society of Laparoendoscopic Surgeons (SLS) as
an Innovative Product of the Year for three years in a row. The Precise 360 was recognized in 2016, The Bovie Ultimate generator was recognized in 2015, and the J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Pistol Grip was
recognized in 2014. As a result of our sales, marketing and product development initiatives in 2016 and 2015, we have significantly increased the number of surgeons using the product, gained approvals for the sale of J-Plasma<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Hospital Value Analysis Committees and signed agreements for the use of J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by the members of Group Purchasing Organizations
that serve the medical community. </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In order to assist us in leveraging J-Plasma&#146;s precision and effectiveness in
multiple surgical specialties, we launched a Medical Advisory Board in 2015 currently comprised of surgeons who are recognized leaders in urology, cardiovascular and cardiothoracic surgery. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are continuing to make substantial investments in the development and marketing of our J-Plasma technology for the long term benefit
of the Company and its stakeholders and this may adversely affect our short term profitability and cash flow, particularly over the next 12 to 24 months. While we believe that these investments have the potential to generate additional revenues and
profits in the future, there can be no assurance that J-Plasma will be successful or that such future revenues and profitability will be realized. From June of 2010 through December 31, 2014, we invested approximately $5.5 million in the development
and marketing of our <FONT STYLE="white-space:nowrap">J-Plasma</FONT> technology and an additional approximately $5.5 million in 2015, bringing the total investment to approximately $11.0 million since inception. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Company Products </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">We group our products into three main categories: electrosurgery, cauteries, and other products. Information regarding sales by product categories and related percentages can be found in our annual and quarterly reports filed with
the SEC. We manufacture and market various medical products, both under private label and the Bovie brands (Bovie, IDS, ICON and DERM), to distributors worldwide. Additionally, Bovie has original equipment manufacturing (OEM) agreements with other
medical device manufacturers. These OEM and private label arrangements and our use of the Bovie brands enable us to gain greater market share for the distribution of our products. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Advanced Energy Products </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B>J-Plasma Products </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>BOVIE ULTIMATE </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In March 2015, we launched The Bovie<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;Ultimate&#153; generator. The
Bovie&nbsp;Ultimate is a high frequency electrosurgical generator that can be used for delivery of RF energy and/or helium gas plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The generator offers
users monopolar, bipolar and J-Plasma features in a single generator. It has both FDA clearance and CE Mark. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>J-Plasma
Disposable Portfolio </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We offer different hand pieces for open and laparoscopic procedures. The helium-based plasma
generated from these devices have been shown to cause less thermal damage to tissue than CO<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> laser, argon plasma and RF energy products currently available on the market. The technology has a
general indication and can be used for cutting, coagulating and ablating soft tissue. The two primary specialties that are targeted in phase one of the product launch are gynecology and plastic surgery. However, given the wide range of tissue
applications for J-Plasma, we are now engaged in ongoing development to create products for oncology, urology, cardiovascular, and cardiothoracic procedures. The advantages of helium plasma continue to be studied throughout the medical and
scientific communities. We believe that surgical applications are just one area of opportunity for this technology. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In
September of 2015, we expanded our offering of laparoscopic hand pieces by introducing the J-Plasma Precise&#153; configurations to the market. In March 2016, we launched the Precise 360 as our seventh new hand piece configuration. These new
configurations expand the procedure base for J-Plasma by providing surgeons with the tools they need to access additional anatomic locations. </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Other Advanced Energy Products </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Bovie has added its second product to the growth portfolio, PlazXact. This product is a Bipolar RF Ablator for orthopedic joint surgery.
The ablators are sterile, single-use devices for the cutting, coagulating and ablation (vaporizing) of soft tissue.&nbsp;The patented, wedge-shaped electrode gives unmatched access and visibility.&nbsp;The design also enables the surgeon to use the
product at lower power level to achieve ablation. This reduces the risk of inadvertent burns due to the lower temperatures of fluid in the joints. The ablators&nbsp;have patented design features that make them highly efficient and therefore&nbsp;do
not require use with specialized high-powered generators. Bovie&#146;s Ablators can be used with most standard electrosurgical generator already present in all operating rooms. PlazXact is the only orthopedic ablator in the market with no dedicated
capital equipment required. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Electrosurgery Products </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Electrosurgery is our largest product line and includes desiccators, generators, electrodes, electrosurgical pencils and various
ancillary disposable products. These electrosurgical products are used during surgical procedures in gynecology, urology, plastic surgery, dermatology, veterinary, and other surgical markets for the cutting and coagulation of tissue. It is estimated
that 80% of all surgical procedures performed worldwide are conducted by electrosurgery. Our electrosurgery products fall under two categories, monopolar and bipolar. Monopolar products require the use of a grounding pad attached to the patient for
the return of the electrical current, while bipolar products consist of two electrodes; one for the inbound current and one for the return current and therefore do not require the use of a grounding pad. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>DERM101 and DERM 102 </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">These effective and economical 10 watt high frequency desiccators provide a low wattage platform for minor in-office skin procedures. We designed these products specifically for family practice physicians, pediatricians and other
general practitioners, enabling them to perform simple skin procedures in their offices instead of referring the patient to a specialist saving the patient time and providing additional revenue generating procedures for the physician. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Aaron 940/ Aaron 950 / Aaron 1250U </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The Aaron 940 is a Bovie developed, low powered 40-watt high frequency desiccator designed primarily for dermatology and family practice
physicians. The units are used mainly for removing small skin lesions and growths as well as for coagulation for office based procedures. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">The Aaron 950 is a 60-watt high frequency desiccator with the added feature of a cut capacity for outpatient surgical procedures. In effect, the 950 is two independent surgical devices in one small package. It is designed mainly for
use in doctors&#146; offices and is utilized in a broad range of specialties including dermatology, gynecology, family practice, urology, plastic surgery and ophthalmology. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The Aaron 1250U is a 120-watt multipurpose electrosurgery generator. The unit features monopolar and bipolar functions with pad sensing.
This product is considered to be ideally suited for office-based procedures in the specialties of gynecology, plastic surgery and urology. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><I>Aaron 2250 /2350/ 3250/3350 and IDS 200 /210/ 300 /310 400 </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To address market demand for more powerful
electrosurgical generators, Bovie developed 200, 300 and 400-watt multipurpose digital electrosurgery generators designed for the rapidly expanding surgi-center market and the hospital outpatient and inpatient markets. This equipment includes
digital hardware that enables very high parallel data processing throughout the operation or procedure. All data is sampled and processed digitally. For </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
the first time in electrosurgery, surgeons are able to measure tissue impedance in real time (5,000 times a second) thanks to the utilization of digital technology. The design of these units is
based on a digital feedback system. By using dedicated digital hardware in place of a general purpose controller for processing data, our equipment enables the power to be adjusted as the impedance varies, to deliver a consistent clinical effect.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The IDS 200/Aaron 2250 are 200-watt generators that have the capability to be used in the majority of procedures performed
today in surgi-center or outpatient settings. Although 200 watts is adequate to do most procedures in the operating room, 300 watts is considered the standard and believed to be what most hospitals and surgi-centers will require. To meet this
requirement, we developed the IDS 300/ Aaron 3250. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">IDS 310/210 and Bovie OR|Pro A3350 and Surgicenter Pro A2350 are the next
generation of surgi-center and operating room generators. These units incorporate the best features of the IDS 300 and upgrade its capabilities by providing additional bipolar options, including the 225-watt Bovie bipolar and an auto bipolar
feature. The 300 watt units also offer the capability to utilize two pencils with simultaneous activation in fulguration mode. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">The Bovie IDS 400 is a 400-watt generator designed primarily for sale in markets outside of the United States. These units feature both monopolar and bipolar functions, have pad and tissue sensing, and include nine blended cutting
settings. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Electrosurgical Disposables </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Resistick&#153; II </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Resistick II is a trademarked and proprietary coating that is applied to stainless steel that resist eschar (scab or scar tissue caused by burning) during surgery. We have experienced strong demand for this product since its
introduction in 2011, and it represents our continued expansion of the Bovie line of electrosurgical disposables. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Disposable Laparoscopic Electrodes </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have introduced a line of disposable laparoscopic electrodes in Resistick coated and stainless steel for use by physicians from a
broad group of specialties including gynecology, general surgery and urology. These electrodes are offered in J-hook, L-hook, needle, ball and spatula design and have an adapter included which makes these laparoscopic electrodes usable with a
3/32&#148; or 4mm plug. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Cauteries </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Battery Operated Cauteries </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Battery operated cauteries constitute our second largest product line. Cauteries were originally designed for precise hemostasis (to stop bleeding) in ophthalmology. The current use of cauteries has been substantially expanded to
include a broad range of applications. Battery operated cauteries are primarily sterile one-time use products. We have continued to improve our offering and now have a snap design cautery which has a patent pending. It features a switch mechanism
that dramatically reduces the potential for accidental activation. We manufacture one of the broadest lines of cauteries in the world, including but not limited to, a line of replaceable battery and replaceable tip cauteries, which are popular in
veterinary and overseas markets. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Other Products </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Battery Operated Medical Lights </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We manufacture and market a variety of specialty lighting instruments for use in ophthalmology as well as distribute specialty lighting
instruments for general surgery, hip replacement surgery and for the placement of endotracheal tubes in emergency and surgical procedures. We also manufacture and market physicians&#146; office use penlights used in physician offices. </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Nerve Locator Stimulator </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We manufacture a nerve locator stimulator primarily used for identifying motor nerves in hand and facial reconstructive surgery. This
instrument is a sterile, self-contained, battery-operated unit, for one time use. </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_3"></A>THE&nbsp;OFFERING </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Common stock offered by the Selling Stockholders in this offering
</B></FONT></P></TD>
<TD><FONT COLOR="#50748a">1,500,000 shares </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Common stock offered the Company in the Concurrent Offering </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">1,500,000 shares </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Common stock to be outstanding after completion of this offering and the Concurrent
Offering </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">28,642,218 shares </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Use of proceeds </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">We will not receive any proceeds from the sale of the 1,500,000 shares of common stock by the Selling Stockholders under this prospectus supplement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>NYSE MKT symbol </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">BVX </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Risk factors </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">Investing in our common stock involves a high degree of risk. See &#147;Risk&nbsp;factors&#148; beginning on page S-9 of this prospectus supplement and page&nbsp;5&nbsp;of the accompanying prospectus and under &#147;Risk
Factors&#148; in our Annual Report on Form 10-K for the year ended December 31, 2015 that is incorporated by reference into this prospectus supplement. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The number of shares of common stock to be outstanding immediately after this offering and the Concurrent Offering as shown above is
based on 27,142,218 shares of common stock outstanding as of September&nbsp;30, 2016. The number of outstanding shares excludes, as of September 30, 2016: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">3,318,447 shares of our common stock reserved for issuance upon the exercise of outstanding stock options; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">254,375 shares of our common stock reserved for issuance pursuant to outstanding common stock purchase warrants; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">3,951,278 shares of our common stock reserved for issuance upon conversion of our shares of Series B Convertible Preferred Stock. Each share of Series B Convertible Preferred Stock is convertible
into two shares of common stock. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Concurrent Offering </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Concurrently with the sale of shares of our common stock by the Selling Stockholders under this prospectus supplement, the Company is
selling 1,500,000 shares of our common stock under another prospectus supplement in the Concurrent Offering. As part of the Concurrent Offering, the Company granted the underwriter an option for a period of thirty (30) days to purchase up to an
additional 225,000 shares of our common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Unless otherwise indicated, all information in this prospectus supplement
assumes that the underwriter does not exercise their over-allotment option in this offering or the Concurrent Offering. </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and
therein, and any free writing prospectus that we have authorized for use in connection with this offering contain forward-looking statements within the meaning of Section 27A of the Securities Act regarding our business, financial condition, results
of operations and prospects. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify&nbsp;forward-looking&nbsp;statements. However, these are not the
exclusive means of identifying forward-looking statements. Although forward-looking statements contained in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and therein, and any free writing
prospectus that we have authorized for use in connection with this offering, reflect our good faith judgment, such statements can only be based on facts and factors currently known to us. Consequently, forward-looking statements are inherently
subject to risks and uncertainties, and actual outcomes may differ materially from the results and outcomes discussed in the&nbsp;forward-looking&nbsp;statements. Further information about the risks and uncertainties that may impact us are described
or incorporated by reference in &#147;Risk Factors&#148; below and in the documents incorporated by reference herein. You should read carefully the risk factors incorporated by reference and set forth herein. You should not place undue reliance
on&nbsp;forward-looking&nbsp;statements, which speak only as of the date of this prospectus supplement. We undertake no obligation to update publicly any forward-looking statements in order to reflect any event or circumstance occurring after the
date of this prospectus supplement or currently unknown facts or conditions or the occurrence of unanticipated events. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_5"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and all other information
contained in this prospectus supplement and the accompanying prospectus, including the risk factors in the section entitled &#147;Risk Factors&#148; in the accompanying prospectus and in the documents incorporated by reference herein and therein.
You should also refer to the other information in this prospectus supplement and the accompanying prospectus, including our financial statements and the related notes incorporated by reference in this prospectus supplement and the accompanying
prospectus. </I></FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Risks Related to Our Industry </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>The medical device industry is highly competitive and we may be unable to compete effectively. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The medical device industry is highly competitive. Many competitors in this industry are well-established, do a substantially greater
amount of business, and have greater financial resources and facilities than we do. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Domestically, we believe we rank third
in the number of units sold in the field of electrosurgical generator manufacturing and we sell our products and compete with other manufacturers in various ways. In addition to advertising, attending trade shows and supporting our distribution
channels, we strive to enhance product quality and functionality, improve user friendliness, and expand product exposure. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We
have also invested, and continue to invest, substantial resources to develop and monetize our J-Plasma technology. If we are unable to gain acceptance in the marketplace of J-Plasma, our business and results of operations may be materially and
adversely affected. From June of 2010 through December 31, 2015, we have invested approximately $11.0 million in the development and marketing of our J-Plasma technology. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We also compete by private labeling our products for major distributors under their label. This allows us to increase our position in
the marketplace and thereby compete from two different approaches, our Aaron or Bovie label, and our customers&#146; private label. Our private label customers distribute our products under their name through their internal sales force. We believe
our main competitors do not private label their products. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Lastly, at this time we sell the majority of our products through
distributors. Many of the companies we compete with sell direct, thus competing directly with distributors they sometimes use. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B><I>Our industry is highly regulated by the U.S. Food and Drug Administration and international regulatory authorities, as well as other governmental, state and federal agencies which have substantial authority to establish
criteria which must be complied with in order for us to continue in operation. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>United States </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our products and research and development activities are subject to regulation by the FDA and other regulatory bodies. FDA regulations
govern, among other things, the following activities: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product development </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product testing </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product labeling </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product storage </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Pre-market clearance or approval </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Advertising and promotion </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product traceability, and </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product indications. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In the United States, medical devices are classified on the basis of control deemed
necessary to reasonably ensure the safety and effectiveness of the device. Class I devices are subject to general controls. These controls include registration and listing, labeling, pre-market notification and adherence to the FDA Quality System
Regulation. Class II devices are subject to general and special controls. Special controls include performance standards, post market surveillance, patient registries and FDA guidelines. Class III devices are those which must receive pre-market
approval by the FDA to ensure their safety and effectiveness. Currently, we only manufacture Class I and Class II devices. Pre-market notification clearance must be obtained for some Class I and most Class II devices when the FDA does not require
pre-market approval. All of our products have been cleared by, or are exempt from, the pre-market notification process. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">A
pre-market approval application is required for most Class III devices. A pre-market approval application must be supported by valid scientific evidence to demonstrate the safety and effectiveness of the device. The pre-market approval application
typically includes: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Results of bench and laboratory tests, animal studies, and clinical studies </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">A complete description of the device and its components; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">A detailed description of the methods, facilities and controls used to manufacture the device, and proposed labeling. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The pre-market approval process can be expensive, uncertain and lengthy. A number of devices for which pre-market approval has been
sought by other companies have never been approved for marketing. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>International Regulation </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To market products in the European Union, our products must bear the &#147;CE&#148; mark. Manufacturers of medical devices bearing the CE
mark have gone through a conformity assessment process that assures that products are manufactured in compliance with a recognized quality system and to comply with the European Medical Devices Directive. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Each device that bears a CE mark has an associated technical documentation that includes a description of the following: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Description of the device and its components, </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">A Summary of how the device complies with the essential requirements of the medical devices directive, </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Safety (risk assessment) and performance of the device, </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Clinical evaluations with respect to the device, </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Methods, facilities and quality controls used to manufacture the device, and </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Proposed labeling for the device. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Manufacturing and
distribution of a device is subject to ongoing surveillance by the appropriate regulatory body to ensure continued compliance with quality system and reporting requirements. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We began CE marking of devices for sale in the European Union in 1999. In addition to the requirement to CE mark, each member country of
the European Union maintains the right to impose additional regulatory requirements. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Outside of the European Union,
regulations vary significantly from country to country. The time required to obtain approval to market products may be longer or shorter than that required in the United States or the European Union. Certain European countries outside of the
European Union do recognize and give effect to the CE mark certification. We are permitted to market and sell our products in those countries. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>If we are unable to successfully introduce new products or fail to keep pace with
competitive advances in technology, our business, financial condition and results of operations could be adversely affected. In addition,&nbsp;our research and development efforts rely upon investments and alliances, and we cannot guarantee that any
previous or future investments or alliances will be successful. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our research and development activities are an
essential component of our efforts to develop new and innovative products for introduction in the marketplace. New and improved products play a critical role in our sales growth. We continue to place emphasis on the development of proprietary
products, such as our J-Plasma technology,&nbsp;and product improvements to complement and expand our existing product lines. We maintain close working relationships with physicians and medical personnel in hospitals and universities who assist in
product research and areas of development. Our research and development activities are primarily conducted internally and are expensed as incurred. These expenses include direct expenses for wages, materials and services associated with the
development of our products net of any reimbursements from customers. Research and development expenses do not include any portion of general and administrative expenses. Our Clearwater, Florida facility has been our flagship research and design
location. We expect to continue making future investments to enable us to develop and market new technologies and products to further our strategic objectives and strengthen our existing business. However, we cannot guarantee that any of our
previous or future investments will be successful or that our new products such as J-Plasma, will gain market acceptance, the failure of which would have a material adverse effect on our business and results of operations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The amount expended by us on research and development of our products during the years 2015, 2014, and 2013, totaled approximately $2.1,
$1.4, and $1.3 million, respectively. During the past three years, we invested substantial resources in the development and marketing of our J-Plasma technology. We have not incurred any direct costs relating to environmental regulations or
requirements. For 2016, we expect the amount of our expenditures for research and development activities to increase modestly when compared to 2015. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Even if we are successful in developing and obtaining approval for our new product candidates, there are various circumstances
that could prevent the successful commercialization of the products. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our ability to successfully commercialize our
products will depend on a number of factors, any of which could delay or prevent commercialization, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">the regulatory approvals of our new products are delayed or we are required to conduct further research and development of our products prior to receiving regulatory approval;
</FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are unable to build a sales and marketing group to successfully launch and sell our new products; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are unable to raise the additional funds needed to successfully develop and commercialize our products or acquire additional products for growth; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are required to allocate available funds to litigation matters; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are unable to manufacture the quantity of product needed in accordance with current good manufacturing practices to meet market demand, or at all; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">our product is determined to be ineffective or unsafe following approval and is removed from the market or we are required to perform additional research and development to further prove the safety
and effectiveness of the product before re-entry into the market; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">competition from other products or technologies prevents or reduces market acceptance of our products; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we do not have and cannot obtain the intellectual property rights needed to manufacture or market our products without infringing on another company&#146;s patents; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are unsuccessful in defending against patent infringement or other intellectual property rights, claims that could be brought against us, our products or technologies; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The failure to successfully acquire or develop and commercialize new products will have a
material and adverse effect on the future growth of our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Our
international operations subject us to foreign currency fluctuations and other risks associated with operating in foreign countries</I></B>. </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">We operate internationally and enter into transactions denominated in foreign currencies. To date, we have not hedged our exposure to changes in foreign currency exchange rates, and as a result, we are subject to foreign currency
transaction and translation gains and losses. We purchase goods and services in U.S. dollars and Euros. Foreign exchange risk is managed primarily by satisfying foreign denominated expenditures with cash flows or assets denominated in the same
currency therefore we are subject to some foreign currency fluctuation risk. Our currency value fluctuations were not material for 2015. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B><I>Our operations and cash flows may be adversely impacted by healthcare reform legislation. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The
Patient Protection and Affordable Care Act and Health Care and Education Affordability Reconciliation Act were enacted into law in the U.S. in March 2010. Among other initiatives, this legislation imposes a 2.3% excise tax on domestic sales of class
I, II, and III medical devices beginning in 2013. The Consolidated Appropriations Act, 2016, signed into law on Dec. 18, 2015, includes a two year moratorium on the medical device excise tax imposed by Internal Revenue Code section 4191. Thus, the
medical device excise tax does not apply to the sale of a taxable medical device by the manufacturer, producer, or importer of the device during the period beginning on Jan. 1, 2016, and ending on Dec. 31, 2017. Substantially all of our products are
class I or class II medical devices and in 2015 and 2014 we paid medical device excise tax of approximately $450,378 and $435,926, respectively. As approximately 83% of our 2015 sales were derived in the U.S. we cannot predict if any additional
regulations will be implemented at the federal or state level, or the effect of any future legislation or regulation in the U.S. or internationally. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Our operations may experience higher costs to produce our products as a result of changes in prices for oil, gasoline, and other
commodities. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We use some plastics and other petroleum-based materials along with precious metals contained in
electronic components as raw materials in many of our products. Prices of oil and gasoline also significantly affect our costs for freight and utilities. Oil, gasoline and precious metal prices are volatile and may increase, resulting in higher
costs to produce and distribute our products. Due to the highly competitive nature of the healthcare industry and the cost-containment efforts of our customers we may be unable to pass along cost increases through higher prices. If we are unable to
fully recover these costs through price increases or offset through other cost reductions, our results of operations could be materially and adversely affected. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Our manufacturing facilities are located in Clearwater, Florida and could be affected due to multiple risks from fire, hurricanes,
physical changes in the planet due to climate change, and similar phenomena. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our manufacturing facilities are located
in Clearwater, Florida and could be affected by multiple weather risks, most notably hurricanes. Although we carry property and casualty insurance and business interruption insurance, future possible disruptions of operations or damage to property,
plant and equipment due to hurricanes or other weather risks could result in impaired production and affect our ability to meet our commitments to our customers and impair important business relationships, the loss of which could adversely affect
our operations and profitability. We do however maintain a backup generator at our Clearwater facility and a disaster recovery plan is in place to help mitigate this risk. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We do not produce hazardous materials or emissions that would adversely impact the environment.&nbsp;We do however, have air
conditioning units and consume electricity which could be impacted by climate change in the form of increased rates. However, we do not believe the increase in expense from any rate increases, as a percentage of sales, would be material in the near
term. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Risks Relating to Our Business </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We have historically done a substantial amount of business with seven of our top ten customers, who are also major distributors of
our product, which as a group have produced substantial revenues for our Company. Loss of business from a major customer will likely materially and adversely affect our business. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We manufacture the majority of our products on our premises in Clearwater, Florida and in Sofia, Bulgaria. Labor-intensive sub-assemblies
and labor-intensive products may be out-sourced to our specification. Although we sell through distributors, we market our products through national trade journal advertising, direct mail, distributor sales representatives and trade shows, under the
Bovie name, the Bovie/Aaron name and private label. Major distributors include Cardinal Health, Independent Medical Co-Op Inc. (IMCO), McKesson Medical Surgical, Inc., Medline, National Distribution and Contracting Inc. (NDC), and Owens &amp; Minor.
If any of these distributor relationships are terminated or not replaced, our revenue from the territories served by these distributors could be adversely affected. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are also dependent on OEM customers who have no legal obligation to purchase products from us. Should such customers fail to give us
purchase orders for the product after development, our future business and value of related assets could be negatively affected. Furthermore, no assurance can be given that such customers will give sufficient high priority to our products. Finally,
disagreements or disputes may arise between us and our customers, which could adversely affect production and sales of our products. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B><I>We rely on certain suppliers and manufacturers for raw materials and other products and are vulnerable to fluctuations in the availability and price of such products and services. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Fluctuations in the price, availability, and quality of the raw materials we use in our manufacturing could have a negative effect on our
cost of sales and our ability to meet the demands of our customers. Inability to meet the demands of our customers could result in the loss of future sales. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition, the costs to manufacture our products depend in part on the market prices of the raw materials used to produce them. We may
not be able to pass along to our customers all or a portion of our higher costs of raw materials due to competitive and marketing pressures, which could decrease our earnings and profitability. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We also have collaborative arrangements with three key foreign suppliers under which we request the development of certain items and
components and we purchase them pursuant to purchase orders. Our purchase order commitments are never more than one year in duration and are supported by our sales forecasts. The majority of our raw materials are purchased from sole-source
suppliers. While we believe we could ultimately procure other sources for these components, should we experience any significant disruptions in this key supply chain, there are no assurances that we could do so in a timely manner which could render
us unable to meet the demands of our customers, resulting in a material and adverse effect on our business and operating results. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B><I>If we are unable to protect our patents or other proprietary rights, or if we infringe on the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have been issued 32 patents in the United States and 22 foreign patents. We have 16 pending patent applications in
the United States and 9 pending foreign applications. Our intellectual property portfolio for the technology and products related to J-Plasma product is included in these totals and continues to grow. Specific to J-Plasma, we have been issued 14
U.S. and 5 foreign patents, and we have 13 U.S. and 6 foreign applications pending. We intend to continue to seek legal protection, primarily through patents, for our proprietary technology. Seeking patent protection is a lengthy and costly process,
and there can be no assurance that patents will be issued from any pending applications, or that any claims allowed from existing or pending patents will be sufficiently broad or strong to protect our proprietary technology. There is also no
guarantee that any patents we hold will not be challenged, invalidated or circumvented, or that the patent rights granted will provide competitive advantages to us. Our competitors have developed and may continue to develop and obtain patents
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
for technologies that are similar or superior to our technologies. In addition, the laws of foreign jurisdictions in which we develop, manufacture or sell our products may not protect our
intellectual property rights to the same extent as do the laws of the United States. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Adverse outcomes in current or future
legal disputes regarding patent and other intellectual property rights could result in the loss of our intellectual property rights, subject us to significant liabilities to third parties, require us to seek licenses from third parties on terms that
may not be reasonable or favorable to us, prevent us from manufacturing, importing or selling our products, or compel us to redesign our products to avoid infringing third parties&#146; intellectual property. As a result, our product offerings may
be delayed, and we may be unable to meet customers&#146; requirements in a timely manner. Regardless of the merit of any related legal proceeding, we have incurred in the past and may be required to incur in the future substantial costs to
prosecute, enforce or defend our intellectual property rights. Even in the absence of infringement by our products of third parties&#146; intellectual property rights, or litigation related to trade secrets, we have elected in the past and may in
the future elect to enter into settlements to avoid the costs and risks of protracted litigation and the diversion of resources and management&#146;s attention. However, if the terms of settlements entered into with certain of our competitors are
not observed or enforced, we may suffer further costs and risks. Any of these circumstances could have a material adverse effect on our business, financial condition and resources or results of operations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our ability to develop intellectual property depends in large part on hiring, retaining and motivating highly qualified design and
engineering staff with the knowledge and technical competence to advance our technology and productivity goals. To protect our trade secrets and proprietary information, generally we have entered into confidentiality agreements with our employees,
as well as with consultants and other parties. If these agreements prove inadequate or are breached, our remedies may not be sufficient to cover our losses. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We have been and may in the future become subject to litigation proceedings that could materially and adversely affect our
business. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Other Litigation </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition to the litigation risks and proceedings mentioned below, we have recently been involved and may in the future become subject
to legal claims or proceedings related to securities, employment, customer or third party contracts, environmental regulations, or other matters. The costs involved in defending these claims have been substantial, which have had an adverse effect on
our profitability. In addition, if other claims are asserted against us, we may be required to defend against such&nbsp;claims, or deem it necessary or advisable to initiate a legal proceeding to protect our rights, the expense and distraction of
such a claim or proceeding, whether or not resolved in our favor, could materially and adversely affect our business, financial condition and operating results. Further, if a claim or proceeding were resolved against us or if we were to settle any
such dispute, we may be required to pay damages and costs or refrain from certain activities, any of which could have a material adverse impact on our business, financial condition and operating results. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Intellectual Property Litigation or Trade Secrets </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have in the past, experienced certain allegations of infringement of intellectual property rights and use of trade secrets and may
receive other such claims, with or without merit, in the future. Previously, claims of infringement of intellectual property rights have sometimes evolved into litigation against us, and they may continue to do so in the future. It is inherently
difficult to assess the outcome of litigation. Although we believe we have had adequate defenses to these claims and that the outcome of the litigation will not have a material adverse impact on our business, financial condition, or results of
operations, there can be no assurances that we will prevail. Any such litigation could result in substantial cost to us, significantly reduce our cash resources, and create a diversion of the efforts of our technical and management personnel, which
could have a material and adverse effect on our business, financial condition and operating results. If we are unable to successfully defend against such claims, we could be prohibited from future sales of the allegedly infringing product or
products, which could materially and adversely affect our future growth. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Product Liability Litigation </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Although we carry liability insurance, due to the nature of our products and their use by professionals, we may, from time to time, be
subject to litigation from persons who sustain injury during medical procedures in hospitals, physician&#146;s offices or in clinics and defending such litigation is expensive, disruptive, time consuming and could adversely affect our business. We
currently maintain product liability insurance with combined coverage limits of $10 million on a claims-made basis. There is no assurance that this coverage will be adequate to protect us from any possible liabilities (individually or in the
aggregate) we might incur in connection with the sale or testing of our products. In addition, we may need increased product liability coverage as additional products are commercialized. This insurance is expensive and in the future may not be
available on acceptable terms, if at all. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Our business is subject to the potential for defects or failures associated
with our products which could lead to recalls or safety alerts and negative publicity. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Manufacturing flaws, component
failures, design defects, off-label uses or inadequate disclosure of product-related information could result in an unsafe condition or the injury or death of a patient. These problems could lead to a recall of, or issuance of a safety alert
relating to our products, and result in significant costs and negative publicity. Due to the strong name recognition of our brands, an adverse event involving one of our products could result in reduced market acceptance and demand for all products
within that brand, and could harm our reputation and our ability to market our products in the future. In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the
suspension or delay of our current regulatory reviews of our applications for new product approvals. We also may undertake voluntarily to recall products or temporarily shut down certain production lines based on internal safety and quality
monitoring and testing data. Any of the foregoing problems could disrupt our business and have a material adverse effect on our business, results of operations, financial condition and cash flows. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We have incurred and may in the future incur impairments to our long-lived assets. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We review our long-lived assets, including intangible assets, for impairment annually or more frequently if events or changes in
circumstances indicate that the carrying amount of these assets may not be recoverable. Additionally, if in any period our stock price decreases to the point where our fair value, as determined by our market capitalization, is less than the book
value of our assets, this could also indicate a potential impairment and we may be required to record an impairment charge in that period which could adversely affect our results of operations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our valuation methodology for assessing impairment requires management to make judgments and assumptions based on historical experience
and to rely heavily on projections of future operating performance. We operate in highly competitive environments and projections of future operating results and cash flows may vary significantly from actual results. Additionally, if our analysis
indicates potential impairment to a long-lived intangible asset, we may be required to record additional charges to earnings in our financial statements, which could negatively impact our results of operations. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Risks Related to Our Stock and this Offering </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>The market price of our stock has been and may continue to be highly volatile. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our common stock is listed on the NYSE MKT Market under the ticker symbol &#147;BVX.&#148; The market price of our stock has been and may
continue to be highly volatile, and announcements by us or by third parties may have a significant impact on our stock price. These announcements may include: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">our listing status on the NYSE MKT Market; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">our operating results falling below the expectations of public market analysts and investors; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">developments in our relationships with or developments affecting our major customers; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">negative regulatory action or regulatory non-approval with respect to our new products; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">government regulation, governmental investigations, or audits related to us or to our products; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">developments related to our patents or other proprietary rights or those of our competitors; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">changes in the position of securities analysts with respect to our stock. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">The stock market has from time to time experienced extreme price and volume fluctuations, which have particularly affected the market prices for the medical technology sector companies, and which have often been unrelated to their
operating performance. These broad market fluctuations may adversely affect the market price of our common stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Historically, when the market price of a stock has been volatile, holders of that stock have often instituted securities class action
litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition, future sales by existing stockholders, warrant holders receiving shares upon the exercise of warrants, or any
new stockholders receiving our shares in any financing transaction may lower the price of our common stock, which could result in losses to our stockholders. As described above, in the Concurrent Offering, the Company is selling shares of its common
stock under another prospectus supplement offered pursuant to the 2014 Registration Statement and 2014 Base Prospectus. Future sales of substantial amounts of common stock in the public market, or the possibility of such sales occurring, could
adversely affect prevailing market prices for our common stock or our future ability to raise capital through an offering of equity securities. Substantially all of our common stock is freely tradable in the public market without restriction under
the Securities Act, unless these shares are held by our &#147;affiliates&#148;, as that term is defined in Rule 144 under the Securities Act. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B><I>We have no present intention to pay dividends on our common stock and, even if we change that policy, we may be unable to pay dividends on our common stock. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We currently do not anticipate paying any dividends on our common stock in the foreseeable future. We currently intend to retain future
earnings, if any, to finance operations and invest in our business. Any declaration and payment of future dividends to holders of our common stock will be at the discretion of our board of directors and will depend on many factors, including our
financial condition, earnings, capital requirements, level of indebtedness, statutory and contractual restrictions applying to the payment of dividends and other considerations that our board of directors deems relevant. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If we change that policy and commence paying dividends, we will not be obligated to continue paying those dividends and our stockholders
will not be guaranteed, or have contractual or other rights, to receive dividends. If we&nbsp;commence paying dividends in the future, our board of directors may decide, in its discretion, at any time, to decrease the amount of dividends, otherwise
modify or repeal the dividend policy or discontinue entirely the payment of dividends. Under the Delaware law, our board of directors may not authorize the payment of a dividend unless it is either paid out of our statutory surplus. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Investors in this offering will experience immediate and substantial dilution. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The public offering price of the securities offered pursuant to this prospectus supplement is substantially higher than the net tangible
book value per share of our common stock. Therefore, if you purchase shares of common stock in this offering, you will incur immediate and substantial dilution in the pro forma net tangible book value per share of common stock from the price per
share that you pay for the common stock. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>The low trading volume of our common stock may adversely affect the price of our
shares and their liquidity. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Although our common stock is listed on the NYSE MKT exchange, our common stock has
experienced low trading volume. Limited trading volume may subject our common stock to greater price volatility and may make it difficult for investors to sell shares at a price that is attractive to them. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We may in the future seek to raise funds through equity offerings, which could have a dilutive effect on our common stock.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In the future we may determine to raise capital through offerings of our common stock, securities convertible into
our common stock or rights to acquire these securities or our common stock. For instance, we are authorized to issue up to 40,000,000 shares of common stock and up to 10,000,000 shares of preferred stock, of which 1,975,639 shares have been
designated as Series B Convertible Preferred Stock. The result of sales of such securities (including the sale of our common stock in the Concurrent Offering, as described above), or the conversion of the Series B Convertible Preferred Stock into
shares of common stock, or the triggering of anti-dilution provisions in such securities would ultimately be dilutive to our common stock by increasing the number of shares outstanding. We cannot predict the effect this dilution may have on the
price of our common stock. In addition, the shares of preferred stock may have rights which are senior or superior to those of the common stock, such as rights relating to voting, the payment of dividends, redemption or liquidation. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Exercise of warrants and options issued by us will dilute the ownership interest of existing stockholders. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As of September 30, 2016, the warrants issued by us in December 2013 were exercisable for up to approximately 254,375 shares of our
common stock, representing approximately 0.9% of our outstanding common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As of September 30, 2016, our outstanding
stock options to our employees, officers, directors and consultants amounted to approximately 3,818,447 shares of our common stock, representing approximately 13.9% of our outstanding common stock.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The exercise of some or all of our warrants and stock options will dilute the ownership interests of existing stockholders. Any sales in
the public market of the common stock issuable upon such conversion or exercise could adversely affect prevailing market prices of our common stock. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_6"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We will not receive any proceeds from the sale of the 1,500,000 shares of common stock subject to resale by the Selling Stockholders
under this prospectus supplement. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_7"></A>SELLING STOCKHOLDERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The shares of common stock being offered by the Selling Stockholders consist of shares of common stock owned by the Selling Stockholders
and not shares of common stock that are issuable to the Selling Stockholders upon conversion of the shares of Series B Convertible Preferred Stock held by such stockholders. Each share of Series B Preferred Stock is convertible into two shares of
common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The Certificate of Designation of Preferences, Rights and Limitations (the &#147;Certificate of
Designation&#148;) of the Series B Preferred Stock provides that a holder of Series B Preferred Stock may not convert any portion of the Series B Preferred Stock to the extent that, after giving effect to such conversion, such holder (together with
any person whose beneficial ownership of common stock would be aggregated with such holder under Section 13(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), would beneficially own in excess of 9.985% of the
common stock outstanding immediately after giving effect to the issuance of shares of common stock (as such percentage may be increased or decreased upon not less than 61 days&#146; prior notice to the Company). This maximum beneficial ownership
percentage is referred to as the &#147;Beneficial Ownership Limitation.&#148; The Selling Stockholders disclaim beneficial ownership of such number of shares of common stock the issuance of which would exceed the Beneficial Ownership Limitation.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The table below lists the Selling Stockholders and other information regarding the beneficial ownership (as determined under
Section 13(d) of the Exchange Act and the rules and regulations thereunder and subject to the Beneficial Ownership Limitation) of the shares of common stock held by each of the Selling Stockholders. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The first column lists the number of shares of common stock beneficially owned by the Selling Stockholders based on their respective
ownership of shares of common stock as of September&nbsp;30, 2016. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The second column lists the number of shares of common
stock being offered by this prospectus supplement by the Selling Stockholders. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The third column lists the number of shares of common stock beneficially owned by Selling Stockholders after this offering, based on
their respective ownership of shares of common stock as of September&nbsp;30, 2016, (i) assuming the issuance of 1,500,000 shares of common stock by the Company in the Concurrent Offering and (ii) giving effect to the Beneficial Ownership
Limitation. </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Beneficial</B></FONT><br><FONT COLOR="#50748a"><B>Ownership Before<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Total<BR>Shares
of<BR>Common<BR>Stock</B></FONT><br><FONT COLOR="#50748a"><B>Offered</B></FONT><br><FONT COLOR="#50748a"><B>By Selling</B></FONT><br><FONT COLOR="#50748a"><B>Stockholder</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Beneficial</B></FONT><br><FONT COLOR="#50748a"><B>Ownership After<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Selling Stockholder</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Shares<SUP STYLE="font-size:85%; vertical-align:top">(1)(8)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Percent<SUP STYLE="font-size:85%; vertical-align:top">(1)(8)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Biomedical Value Fund,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1,286,079<SUP STYLE="font-size:85%; vertical-align:top"></SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">4.732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">710,964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1,443,858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">4.732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Biomedical Institutional Value Fund, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">330,738<SUP STYLE="font-size:85%; vertical-align:top"></SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1.217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">182,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">371,315</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1.217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Biomedical Offshore Value Fund, Ltd.<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">719,462<SUP STYLE="font-size:85%; vertical-align:top"></SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">2.647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">397,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">807,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">2.647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">WS Investments II,
LLC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">39,858<SUP STYLE="font-size:85%; vertical-align:top"></SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0.147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">21,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">44,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0.147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Class D Series of GEF-PS,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">337,357<SUP STYLE="font-size:85%; vertical-align:top"></SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1.241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">186,496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">378,475</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1.241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #50748a;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Assumes that all the shares of common stock covered by this prospectus supplement are sold and that the Selling Stockholders do not acquire any additional shares of common stock before the
completion of this offering. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Great Point Partners, LLC (&#147;Great Point&#148;) is the investment manager of each of Biomedical Institutional Value Fund,&nbsp;L.P., Biomedical Offshore Value Fund,&nbsp;Ltd., Biomedical Value
Fund,&nbsp;L.P., Class&nbsp;D Series of GEF-PS,&nbsp;L.P. and WS Investments II,&nbsp;LLC (collectively, the &#147;Great Point Selling Stockholders&#148;), and has the power to vote or dispose of the shares listed above. Each of Dr. Jeffrey R. Jay,
M.D. (&#147;Dr. Jay&#148;), as senior managing member of Great Point, and Mr. David Kroin (&#147;Mr. Kroin&#148;), as special managing member of Great Point, has voting and investment power with respect to the shares owned by each of the Great Point
Selling Stockholders. Each of Great Point, Dr. Jay and Mr.&nbsp;Kroin disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interest therein. The address for the Great Point Selling Stockholders is 165
Mason Street, 3rd&nbsp;Floor, Greenwich, CT 06830. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 1,270,255 shares of common stock and 15,824 shares of common stock issuable upon the conversion of Series B Preferred Stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 326,669 shares of common stock and 4,069 shares of common stock issuable upon the conversion of Series B Preferred Stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 710,610 shares of common stock and 8,852 shares of common stock issuable upon the conversion of Series B Preferred Stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 39,260 shares of common stock and 598 shares of common stock issuable upon the conversion of Series B Preferred Stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 333,206 shares of common stock and 4,151 shares of common stock issuable upon the conversion of Series B Preferred Stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">If the Beneficial Ownership Limitation were not applicable, after the offering and the Concurrent Offering, the Selling Stockholders would beneficially own the following number of shares of common
stock (including shares of common stock issuable upon conversion of the Series B Preferred Stock): Biomedical Value Fund, L.P. 2,426,026 shares (7.444%), Biomedical Institutional Value Fund, L.P. 623,897 shares (1.914%), Biomedical Offshore Value
Fund, Ltd., 1,357,176 shares (4.164%), WS Investments II, LLC 87,800 shares (0.269%) and Class D Series of GEF-PS, L.P. 636,379 shares (1.952%) (an aggregate of 5,131,278 shares (15.743%)). </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our net tangible book value of our common stock as of September 30, 2016 was approximately $18,692,067, or approximately $0.69 per share
of common stock, based upon 27,142,218 shares outstanding. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares of our common stock outstanding as of September 30,
2016. After giving effect to the sale by the Selling Stockholders of the 1,500,000 shares of our common stock being offered in this offering and the sale of 1,500,000 shares of our common stock by us in the Concurrent Offering, our as-adjusted net
tangible book value would have been approximately $24,164,668, or approximately $0.84 per share of common stock. This represents an immediate increase in net tangible book value of $0.16 per share to our existing stockholders and an immediate
dilution in net tangible book value of $3.16 per share to new investors. The following table illustrates this calculation on a per share basis: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Public offering price per share</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Net tangible book value per share as of September 30, 2016</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0.69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Increase in net tangible book value per share attributable to this offering
and the Concurrent Offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As-adjusted net tangible book value per share after giving effect to this
offering and the Concurrent Offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0.84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Dilution in net tangible book value per share to new
investors</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">3.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If the underwriter exercises in full the option to purchase 225,000 additional shares of common stock
from the Selling Stockholders at the public offering price of $4.00 per share, and&nbsp;an additional 225,000 shares of common stock from the us in the Concurrent Offering,&nbsp;the as-adjusted net tangible book value after this offering and the
Concurrent Offering would be $25,010,668 per share, representing an increase in net tangible book value of $0.18 per share to existing stockholders and immediate dilution in net tangible book value of $3.13 per share to investors purchasing our
common stock at the public offering price in this offering and in the Concurrent Offering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The foregoing table excludes the
following, each as of September 30, 2016: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">3,818,447 shares of our common stock reserved for issuance upon the exercise of outstanding stock options; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">254,375 shares of our common stock reserved for issuance pursuant to outstanding common stock purchase warrants; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">3,951,278 shares of our common stock reserved for issuance upon conversion of our outstanding shares of Series B Convertible Preferred Stock. Each share of Series B Convertible Preferred Stock is
convertible into two shares of common stock. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_9"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Piper Jaffray &amp; Co. is the underwriter of this offering and the Concurrent Offering. Subject to the terms and conditions stated in
the underwriting agreement dated the date of this prospectus supplement, the underwriter has agreed to purchase in this offering, and we have agreed to sell to the underwriter, the number of shares set forth opposite the underwriter&#146;s name.
</FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT COLOR="#50748a"><B>Underwriter</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Number</B></FONT><br><FONT COLOR="#50748a"><B>of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Piper Jaffray &amp; Co.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Total</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The underwriter has advised us that it proposes to offer the shares of common stock to the public at
$4.00 per share and to certain dealers at that price less a concession not in excess of&nbsp;$0.12&nbsp;per share. After the offering, this figure may be changed by the underwriter. The underwriter reserves the right to withdraw, cancel or modify
offers to the public and to reject orders in whole or in part. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The Selling Stockholders have granted to the underwriter an
option to purchase up to an additional 225,000 shares of common stock from the Selling Stockholders at the same price to the public, and with the same underwriting discount, as set forth in the table below. The underwriter may exercise this option
any time during the 30-day period after the date of this prospectus supplement, but only to cover over-allotments, if any. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The following table shows the underwriting discounts and commissions that the Selling Stockholders are to pay to the underwriter in
connection with this offering. These amounts are shown assuming both no exercise and full exercise of the underwriter&#146;s option to purchase additional shares. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>No&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Full&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Per share</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Total</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">360,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">414,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We will receive no proceeds from any sales in this offering. The Selling Stockholders and the Company in
the Concurrent Offering have each agreed to indemnify the underwriter against certain liabilities, including civil liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the underwriter may be required to make in
respect of those liabilities. The Selling Stockholders and the Company have also agreed to reimburse the underwriter in an amount up to an aggregate of $125,000 for fees incurred by them in connection with this offering and the Concurrent Offering.
The Selling Stockholders and the Company&#146;s reimbursement obligations will be pro rata to the number of shares being offered by each of the Selling Stockholders and the Company. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We and each of our directors, executive officers and the Selling Stockholders have agreed, subject to certain exceptions, to not to sell
additional shares of our common stock for a period of 90 days after the date of this prospectus supplement. We have agreed not to directly or indirectly offer for sale, sell, contract to sell, grant any option for the sale of, or otherwise issue or
dispose of, any shares of common stock, options or warrants to acquire shares of common stock, or any related security or instrument, without the prior written consent of Piper Jaffray &amp; Co. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The shares of our common stock are listed on the NYSE MKT Market under the symbol &#147;BVX&#148;. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To facilitate this offering and the Concurrent Offering, the underwriter may engage in transactions that stabilize, maintain or
otherwise affect the price of the common stock during and after the offering. Specifically, the underwriter may over-allot or otherwise create a short position in the common stock for its own account by selling more shares of common stock than have
been sold to it by the Selling Stockholders and us in the Concurrent Offering. The underwriter may elect to cover any such short position by purchasing shares of common stock in the open market or by exercising the over-allotment option granted to
the underwriter. In addition, the underwriter may stabilize or maintain the price of the common stock by bidding for or purchasing </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
shares of common stock in the open market and may impose penalty bids. If penalty bids are imposed, selling concessions allowed to syndicate members or other broker-dealers participating in the
offering are reclaimed if shares of common stock previously distributed in the offering are repurchased, whether in connection with stabilization transactions or otherwise. The effect of these transactions may be to stabilize or maintain the market
price of the common stock at a level above that which might otherwise prevail in the open market. The imposition of a penalty bid may also effect the price of the common stock to the extent that it discourages resales of the common stock. The
magnitude or effect of any stabilization or other transactions is uncertain. These transactions may be effected on the NYSE MKT or otherwise and, if commenced, may be discontinued at any time </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition, in connection with this offering, the underwriter (and selling group members) may engage in passive market making
transactions in the shares on the NYSE MKT Market, prior to the pricing and completion of the offering. Passive market making consists of displaying bids on the NYSE MKT Market no higher than the bid prices of independent market makers and making
purchases at prices no higher than those independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are limited to a specified percentage of the passive market maker&#146;s average daily trading
volume in the shares during a specified period and must be discontinued when that limit is reached. Passive market making may cause the price of the shares to be higher than the price that otherwise would exist in the open market in the absence of
those transactions. If the underwriter commences passive market making transactions, they may discontinue them at any time. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The underwriter may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business
for which they may receive customary fees and reimbursement of expenses. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Selling Restrictions </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Notice to Prospective Investors in the European Economic Area </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &#147;Relevant
Member State&#148;), the underwriter represents and agrees that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, it has not made and will not make an offer of securities which
are the subject of the offering contemplated by this prospectus supplement to the public in that Relevant Member State other than: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined
in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall require us or any underwriter to publish a prospectus pursuant to
Article 3 of the Prospectus Directive. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">For the purposes of this provision, the expression an &#147;offer to
the public&#148; in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to
decide to purchase or subscribe the securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression Prospectus Directive means Directive 2003/71/EC (and amendments
thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means
Directive 2010/73/EU. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Notice to Prospective Investors in the United Kingdom </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The underwriter represents, warrants and agrees as follows: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of
Section&nbsp;21 of the Financial Services and Markets Act 2000 (&#147;FSMA&#148;) received by it in connection with the issue or sale of the securities in circumstances in which Section&nbsp;21 of the FSMA does not apply to us; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">it has complied with, and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United
Kingdom. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Notice to Prospective Investors in Canada </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument 45-106 <I>Prospectus Exemptions </I>or subsection 73.3(1) of the <I>Securities Act </I>(Ontario), and are permitted clients, as defined in National Instrument 31-103 <I>Registration Requirements, Exemptions and Ongoing
Registrant Obligations</I>. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if
this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Pursuant to section 3A.3 of National Instrument 33-105 <I>Underwriting Conflicts </I>(NI 33-105), the underwriter is not required to
comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_10"></A>INCORPORATION OF CERTAIN INFORMATION BY
REFERENCE </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The SEC allows us to incorporate by reference the information we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus supplement and the accompanying prospectus, and information in documents that we file
later with the SEC will automatically update and supersede the information in this prospectus supplement and the accompanying prospectus. We incorporate by reference into this prospectus supplement the documents listed below and any future filings
we make with the SEC under Section 13(a), 13(c) 14 or 15(d) of the Securities Exchange Act of 1934, as amended, until this offering is completed and all securities are sold or until the sale of securities pursuant to this prospectus supplement is
terminated by us: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on February&nbsp;27, 2015; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Amendments No. 1 on Form 10-K/A to our Annual Reports on Form 10-K for the years ended December 31, 2015, 2014, and 2013, each filed with the SEC on October 31, 2016; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Quarterly Reports on Form 10-Q for the quarter ended September 30, 2016 filed with the SEC on October 27, 2016 and for the quarter ended March 31, 2016 filed with the SEC on May 11, 2016;
</FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Current Reports on Form 8-K filed with the SEC on August 2, 2016, August 1, 2016, July 5, 2016, May 11, 2016, and April 21, 2016; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 filed with the SEC on October August 2, 2016; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our definitive proxy statement on Schedule 14A filed with the SEC on May 24, 2016; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Specialized Disclosure Report on Form SD filed with the SEC on August 2, 2016; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">description of our common stock contained in our Registration Statement on Form 8-A pursuant to Section 12(b) of the Exchange Act, as originally filed on November 3, 2003 and as thereafter amended.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Upon request, we will provide, free of charge, to each person to whom a prospectus supplement and accompanying
prospectus is delivered, including a beneficial owner, a copy of any or all information that has been incorporated by reference in the prospectus supplement and accompanying prospectus but not delivered with the prospectus supplement and
accompanying prospectus. Any such request may be made orally or in writing to Bovie&nbsp;Medical Corporation, 4 Manhattanville Road, Suite 106, Purchase, New York 10577, Attention:&nbsp;Jay D. Ewers, Chief Financial Officer, Tel. No.: (727)
803-8636. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_11"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are
available to the public over the Internet at the SEC&#146;s website at www.sec.gov. You may also read and copy any document we file at the SEC&#146;s public reference room at 100 F Street, N.E., Washington, D.C. 205409. Please call the SEC at
1-800-SEC-0330 for further information on the public reference room. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The registration statement to which this prospectus
supplement forms a part and the documents referred to above under &#147;Incorporation of certain information by reference&#148; are also available on our website at http://www.boviemedical.com. We have not incorporated by reference into this
prospectus supplement and accompanying prospectus the information on our website, and you should not consider it to be a part of this prospectus supplement and accompanying prospectus. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supprom282794_12"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The validity of the issuance of securities offered hereby will be passed upon for us by Ruskin Moscou Faltischek, P.C., Uniondale, New
York. Certain legal matters will be passed upon for the underwriter by Goodwin Procter LLP, New York, New York. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#50748a"><B><A NAME="supprom282794_13"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The consolidated financial statements incorporated in this
prospectus supplement by reference from Bovie Medical Corporation&#146;s Annual Report on Form l0-K for the year ended December 31, 2015 have been audited by Frazier&nbsp;Deeter, LLC, independent registered public accountants, as stated in their
report, which is incorporated herein by reference, and have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>PROSPECTUS </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g282794g31r32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>BOVIE MEDICAL CORPORATION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>7,563,153 Shares of Common Stock of Bovie Corporation </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #50748a;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This prospectus relates to the resale by the selling stockholders named in this prospectus or their pledgees, donees,
transferees, or other successors in interest, of up to 7,563,153 shares of our common stock (i) issuable upon conversion of shares of our Series B Convertible Preferred Stock, which they acquired in an exchange transaction in which such selling
stockholders exchanged an aggregate of 3,500,000 shares of our Series A 6% Convertible Preferred Stock and 5,250,000 common stock purchase warrants for an aggregate of 3,588,139 shares of our Series B Convertible Preferred Stock, and (ii) issuable
upon the exercise of five and one-half-year warrants. The securities registered also include a certain number of shares of common stock as may be issued pursuant to the anti-dilution and adjustment provisions provided in the Series B Convertible
Preferred Stock. We will not receive any proceeds from any such sale of these shares, however we may receive payment in cash upon exercise of the warrants. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our common stock is listed on the NYSE MKT under the symbol &#147;BVX.&#148; The last reported sale price of our common
stock on April 10, 2015 was $2.43 per share. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #50748a;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B>INVESTING IN OUR SECURITIES INVOLVES CERTAIN RISKS. YOU SHOULD READ THIS PROSPECTUS, ANY PROSPECTUS SUPPLEMENT AND ALL OTHER INFORMATION INCLUDED OR INCORPORATED BY REFERENCE INTO THIS PROSPECTUS CAREFULLY BEFORE YOU INVEST,
INCLUDING THE <A HREF="#toc282794_2">RISK FACTORS</A> WHICH BEGIN ON PAGE 5 OF THIS PROSPECTUS. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The
shares of common stock may be offered by the selling stockholders in negotiated transactions, at either prevailing market prices or negotiated prices. Each selling stockholder in its discretion may also offer the shares of common stock from time to
time in ordinary brokerage transactions on the NYSE MKT or otherwise. See our discussion in the &#147;Plan of Distribution&#148; section of this prospectus. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The selling stockholders and any brokers executing selling orders on behalf of the selling stockholders may be deemed to
be &#147;underwriters&#148; within the meaning of the Securities Act of 1933, as amended, and commissions received by a broker executing selling orders may be deemed to be underwriting commissions under the Securities Act. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF
THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>THE DATE OF THIS PROSPECTUS IS APRIL 24, 2015 </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #50748a"><FONT COLOR="#50748a"><B>Page&nbsp;No.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_1">PROSPECTUS SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_2">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_4">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_5">SELLING STOCKHOLDERS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_6">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_7">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_8">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_9">WHERE YOU CAN FIND MORE
INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc282794_10">INCORPORATION OF CERTAIN INFORMATION BY
REFERENCE</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">You should read this prospectus, including all documents incorporated herein by reference, together with
additional information described under &#147;Where You Can Find More Information.&#148; </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">You may obtain the information
incorporated by reference without charge by following the instructions under &#147;Where You Can Find More Information.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_1"></A>SUMMARY </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The following summary highlights selected information contained elsewhere or incorporated by reference in this prospectus. This summary
does not contain all the information you should consider before investing in our securities. You should read the entire prospectus and the documents incorporated by reference in this prospectus carefully before making an investment decision.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>You should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized
anyone else to provide you with different or additional information. We are not making an offer to sell these securities in any jurisdiction where the offer is not permitted. You should not assume that the information contained in this prospectus or
in the documents incorporated by reference herein is accurate as of any date other than the date on the front of this prospectus or the filing date of any document incorporated by reference, regardless of its time of delivery, and you should not
consider any information in this prospectus or in the documents incorporated by reference herein to be investment, legal or tax advice. We encourage you to consult your own counsel, accountant and other advisors for legal, tax, business, financial
and related advice regarding an investment in our securities. </B></FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our Company </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We were incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 4 Manhattanville Road,
Suite #106, Purchase, New York 10577. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are an energy-based medical device company specializing in developing,
manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used in doctor&#146;s offices, surgery centers and hospitals worldwide. Our medical devices are marketed through Bovie&#146;s own
well-respected brands (Bovie<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Aaron<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, IDS<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP><SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP>and ICON<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>) and on a private label basis to distributors throughout the world. The Company also leverages its expertise in the design,
development and manufacturing of electrosurgical equipment by producing equipment for large, well-known medical device manufacturers through original equipment manufacturing (OEM) agreements. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are also the developer of J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>; a patented new plasma-based surgical
product which we believe has the potential to be a transformational product for surgeons. J-Plasma utilizes a helium ionization process that produces a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal
invasiveness and an absence of conductive currents during surgery. While currently in the early stages of commercialization, J-Plasma has been the subject of five independent white papers and has been cited therein for its clinical utility in
gynecological surgeries and dermatologic/facial plastic surgery procedures. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our objective is to achieve profitable,
sustainable growth by increasing our market share in the advanced energy category, including the commercialization of products that have the potential to be transformational with respect to the results they produce for surgeons and patients. In
order to achieve this objective, we plan to leverage our long history in the industry, along with the reputation for quality and reliability that the Bovie brand enjoys within the medical community. At the same time, we will expand our products
beyond radio frequency, move forward with research and developments projects aimed at creating value within our existing product portfolio and building our pipeline of new complementary products, and utilize multiple channels to bring new and
existing products to market. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Significant Subsidiaries </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Aaron Medical Industries, Inc. is a wholly-owned Florida corporation based in Clearwater, Florida. It is principally engaged in the
business of marketing our medical products. </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Company Products </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We group our products into three main categories: electrosurgery, cauteries, and other products. Information regarding sales by product
categories and related percentages can be found in our annual and quarterly reports filed with the SEC. We manufacture and market various medical products, both under private label and the Bovie brands (Bovie, Aaron, IDS, ICON and DERM), to
distributors worldwide. Additionally, Bovie has original equipment manufacturing (OEM) agreements with other medical device manufacturers. These OEM and private label arrangements and our use of the Bovie brands enable us to gain greater market
share for the distribution of our products. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Electrosurgery Products </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Electrosurgery is our largest product line and includes desiccators, generators, electrodes, electrosurgical pencils and various
ancillary disposable products. These electrosurgical products are used during surgical procedures in gynecology, urology, plastic surgery, dermatology, veterinary, and other surgical markets for the cutting and coagulation of tissue. It is estimated
that 80% of all surgical procedures performed worldwide are conducted by electrosurgery. Our electrosurgery products fall under two categories, monopolar and bipolar. Monopolar products require the use of a grounding pad attached to the patient for
the return of the electrical current, while bipolar products consist of two electrodes; one for the inbound current and one for the return current and therefore do not require the use of a grounding pad. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Electrosurgical Disposables </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Resistick&#153;&nbsp;II </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Resistick II is a trademarked and proprietary coating that is applied to stainless steel that resist eschar (scab or scar tissue caused by burning) during surgery. We have experienced strong demand for this product since its
introduction in 2011, and it represents our continued expansion of the Bovie line of electrosurgical disposables. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Disposable Laparoscopic Electrodes </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are introducing a line of disposable laparoscopic electrodes in the first quarter of 2015 in Resitick coated and stainless steel for
use by physicians from a broad group of specialties including gynecology, general surgery and urology. These electrodes will be offered in J-hook, L-hook, needle, ball and spatula design and have an adapter included which makes these laparoscopic
electrodes usable with a 3/32&#148; or 4mm plug. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Cauteries </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Battery Operated Cauteries </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Battery operated cauteries constitute our second largest product line. Cauteries were originally designed for precise hemostasis (to stop bleeding) in ophthalmology. The current use of cauteries has been substantially expanded to
include a broad range of applications Battery operated cauteries are primarily sterile one-time use products. We have continued to improve our offering and now have a snap design cautery which has a patent pending. It features a switch mechanism
that dramatically reduces the potential for accidental activation. We manufacture one of the broadest lines of cauteries in the world, including but not limited to, a line of replaceable battery and replaceable tip cauteries, which are popular in
veterinary and overseas markets. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Other Products </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Battery Operated Medical Lights </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We manufacture and market a variety of specialty lighting instruments for use in ophthalmology as well as distribute specialty lighting
instruments for general surgery, hip replacement surgery and for the placement of endotracheal tubes in emergency and surgical procedures. We also manufacture and market physicians&#146; office use penlights. </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Nerve Locator Stimulator </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We manufacture a nerve locator stimulator primarily used for identifying motor nerves in hand and facial reconstructive surgery. This
instrument is a sterile, self-contained, battery-operated unit, for one time use. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>J-Plasma Products </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>ICON GS </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Bovie&#146;s J-Plasma technology is the foundation for the ICON GS plasma system, which utilizes a helium ionization process producing a
stable thin focused beam of ionized gas that can be controlled in a wide range of temperatures and intensities, providing the surgeon greater control and predictability with minimal thermal damage to surrounding tissue. The development of this
helium plasma generator also includes the design of a new proprietary handpiece. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The 510(k) cleared and CE mark approved
Bovie Ultimate generator will eventually replace the ICON GS plasma system. In addition to the J-Plasma technology, the Bovie Ultimate will have the IDS 310 capability, offering users monopolar, bipolar and plasma features, all in one generator.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>J-Plasma Disposable Portfolio </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We offer different hand pieces for open and laparoscopic procedures. The helium-based plasma generated from these devices have been shown
to cause less thermal damage to tissue than C02 laser, argon plasma and RF energy products currently available on the market. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The most recent product launched in the J-plasma portfolio is the Pistol Grip handpiece. This product offers improved ergonomics and is
providing an increased rate of adoption of the technology. Bovie will continue to launch products from a rich pipeline that will allow surgeons to treat from a variety of surgical specialties. </FONT></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #50748a;BORDER-LEFT:1.00pt solid #50748a;BORDER-RIGHT:1.00pt solid #50748a;BORDER-TOP:1.00pt solid #50748a;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>About This Offering </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This prospectus relates to the resale by the selling stockholders identified in this prospectus of up to 7,563,153 shares of common stock
issuable upon (i) conversion of 3,588,139 shares of our Series B Convertible Preferred Stock which were issued in a March 2015 transaction in exchange for and cancellation of an aggregate of 3,500,000 shares of our Series A 6% Convertible Preferred
Stock and 5,250,000 warrants and (ii) and upon the exercise of five and one-half-year warrants (the &#147;Offering&#148;). All of the shares, when sold, will be sold by these selling stockholders. The selling stockholders may sell their shares of
common stock from time to time at prevailing market prices. We will not receive any proceeds from the sale of the shares of common stock by the selling stockholders. However, we may receive the sale price of any common stock we issue to the selling
stockholders upon exercise of the outstanding warrants. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Common Stock Offered: </FONT></P></TD>
<TD><FONT COLOR="#50748a">Up to 7,563,153 shares of common stock, issuable upon conversion of shares of our Series B Convertible Preferred Stock and exercise of warrants. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Common Stock Outstanding at April 13,<BR> 2015: </FONT></P></TD>
<TD><FONT COLOR="#50748a">23,391,035 </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Use of Proceeds: </FONT></P></TD>
<TD><FONT COLOR="#50748a">We will not receive any proceeds from the sale of the 7,563,153 shares of common stock subject to resale by the selling stockholders under this prospectus. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Risk Factors: </FONT></P></TD>
<TD><FONT COLOR="#50748a">An investment in the common stock offered under this prospectus is highly speculative and involves substantial risk. Please carefully consider the &#147;Risk Factors&#148; section and other information in this prospectus
for a discussion of risks. Additional risks and uncertainties not presently known to us or that we currently deem to be immaterial may also impair our business and operations. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">NYSE MKT Symbol: </FONT></P></TD>
<TD><FONT COLOR="#50748a">BVX </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_2"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and all other information
contained in this prospectus and in the documents incorporated by reference herein. You should also refer to the other information in this prospectus, including our financial statements and the related notes incorporated by reference in this
prospectus. </I></FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Risks Related to our Business and Industry </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>The medical device industry is highly competitive and we may be unable to compete effectively. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The medical device industry is highly competitive. Many competitors in this industry are well-established, do a substantially greater
amount of business, and have greater financial resources and facilities than we do. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Domestically, we believe we rank third
in the number of units sold in the field of electrosurgical generator manufacturing and we sell our products and compete with other manufacturers in various ways. In addition to advertising, attending trade shows and supporting our distribution
channels, we strive to enhance product quality and functionality, improve user friendliness, and expand product exposure. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We
have also invested, and continue to invest, substantial resources to develop and monetize, our J-Plasma technology. If we are unable to gain acceptance in the marketplace of J-Plasma, our business and results of operations may be materially and
adversely affected. From June of 2010 through December 31, 2014, we have invested approximately $5.5 million in the development and marketing of our J-Plasma technology. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We also compete by private labeling our products for major distributors under their label. This allows us to increase our position in
the marketplace and thereby compete from two different approaches, our Aaron or Bovie label, and our customers&#146; private label. Our private label customers distribute our products under their name through their internal sales force. We believe
our main competitors do not private label their products. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Lastly, at this time we sell the majority of our products through
distributors. Many of the companies we compete with sell direct, thus competing directly with distributors they sometimes use. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B><I>Our industry is highly regulated by the U.S. Food and Drug Administration and international regulatory authorities, as well as other governmental, state and federal agencies which have substantial authority to establish
criteria which must be complied with in order for us to continue in operation. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>United States </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our products and research and development activities are subject to regulation by the FDA and other regulatory bodies. FDA regulations
govern, among other things, the following activities: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product development </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product testing </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product labeling </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product storage </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Pre-market clearance or approval </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Advertising and promotion </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product traceability, and </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Product indications. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In the United States, medical devices are classified on the basis of control deemed
necessary to reasonably ensure the safety and effectiveness of the device. Class I devices are subject to general controls. These controls include registration and listing, labeling, pre-market notification and adherence to the FDA Quality System
Regulation. Class II devices are subject to general and special controls. Special controls include performance standards, post market surveillance, patient registries and FDA guidelines. Class III devices are those which must receive pre-market
approval by the FDA to ensure their safety and effectiveness. Currently, we only manufacture Class I and Class II devices. Pre-market notification clearance must be obtained for some Class I and most Class II devices when the FDA does not require
pre-market approval. All of our products have been cleared by, or are exempt from, the pre-market notification process. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">A
pre-market approval application is required for most Class III devices. A pre-market approval application must be supported by valid scientific evidence to demonstrate the safety and effectiveness of the device. The pre-market approval application
typically includes: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Results of bench and laboratory tests, animal studies, and clinical studies </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">A complete description of the device and its components; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">A detailed description of the methods, facilities and controls used to manufacture the device, and proposed labeling. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The pre-market approval process can be expensive, uncertain and lengthy. A number of devices for which pre-market approval has been
sought by other companies have never been approved for marketing. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>International Regulation </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To market products in the European Union, our products must bear the &#147;CE&#148; mark. Manufacturers of medical devices bearing the CE
mark have gone through a conformity assessment process that assures that products are manufactured in compliance with a recognized quality system and to comply with the European Medical Devices Directive. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Each device that bears a CE mark has an associated technical documentation that includes a description of the following: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Description of the device and its components, </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">A summary of how the device complies with the essential requirements of the medical devices directive, </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Safety (risk assessment) and performance of the device, </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Clinical evaluations with respect to the device, </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Methods, facilities and quality controls used to manufacture the device, and </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Proposed labeling for the device. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Manufacturing and
distribution of a device is subject to ongoing surveillance by the appropriate regulatory body to ensure continued compliance with quality system and reporting requirements. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We began CE marking of devices for sale in the European Union in 1999. In addition to the requirement to CE mark, each member country of
the European Union maintains the right to impose additional regulatory requirements. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Outside of the European Union,
regulations vary significantly from country to country. The time required to obtain approval to market products may be longer or shorter than that required in the United States or the European Union. Certain European countries outside of the
European Union do recognize and give effect to the CE mark certification. We are permitted to market and sell our products in those countries. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>If we are unable to successfully introduce new products or fail to keep pace with
competitive advances in technology, our business, financial condition and results of operations could be adversely affected. In addition,&nbsp;our research and development efforts rely upon investments and alliances, and we cannot guarantee that any
previous or future investments or alliances will be successful. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our research and development activities are an
essential component of our efforts to develop new and innovative products for introduction in the marketplace. New and improved products play a critical role in our sales growth. We continue to place emphasis on the development of proprietary
products, such as our J-Plasma technology,&nbsp;and product improvements to complement and expand our existing product lines. We maintain close working relationships with physicians and medical personnel in hospitals and universities who assist in
product research and areas of development. Our research and development activities are primarily conducted internally and are expensed as incurred. These expenses include direct expenses for wages, materials and services associated with the
development of our products net of any reimbursements from customers. Research and development expenses do not include any portion of general and administrative expenses. Our Clearwater, Florida facility has been our flagship research and design
location. We expect to continue making future investments to enable us to develop and market new technologies and products to further our strategic objectives and strengthen our existing business. However, we cannot guarantee that any of our
previous or future investments will be successful or that our new products such as J-Plasma, will gain market acceptance, the failure of which would have a material adverse effect on our business and results of operations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The amount expended by us on research and development of our products during the years 2014, 2013, and 2012, totaled approximately $1.4,
$1.3, and $1.3 million respectively. During the past three years, we invested substantial resources in the development and marketing of our J-Plasma technology, including the ICON GS plasma system, Endoscopic Modular Instruments and accompanying new
generators. We have not incurred any direct costs relating to environmental regulations or requirements. For 2015, we expect the amount of our expenditures for research and development activities to remain similar to the level in 2014. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Even if we are successful in developing and obtaining approval for our new product candidates, there are various circumstances
that could prevent the successful commercialization of the products. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our ability to successfully commercialize our
products will depend on a number of factors, any of which could delay or prevent commercialization, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">the regulatory approvals of our new products are delayed or we are required to conduct further research and development of our products prior to receiving regulatory approval;
</FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are unable to build a sales and marketing group to successfully launch and sell our new products; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are unable to raise the additional funds needed to successfully develop and commercialize our products or acquire additional products for growth; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are required to allocate available funds to litigation matters; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are unable to manufacture the quantity of product needed in accordance with current good manufacturing practices to meet market demand, or at all; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">our product is determined to be ineffective or unsafe following approval and is removed from the market or we are required to perform additional research and development to further prove the safety
and effectiveness of the product before re-entry into the market; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">competition from other products or technologies prevents or reduces market acceptance of our products; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we do not have and cannot obtain the intellectual property rights needed to manufacture or market our products without infringing on another company&#146;s patents; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">we are unsuccessful in defending against patent infringement or other intellectual property rights, claims that could be brought against us, our products or technologies; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The failure to successfully acquire or develop and commercialize new products will have a
material and adverse effect on the future growth of our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Our
international operations subject us to foreign currency fluctuations and other risks associated with operating in foreign countries. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">We operate internationally and enter into transactions denominated in foreign currencies. To date, we have not hedged our exposure to changes in foreign currency exchange rates, and as a result, we are subject to foreign currency
transaction and translation gains and losses. We purchase goods and services in U.S. dollars and Euros. Foreign exchange risk is managed primarily by satisfying foreign denominated expenditures with cash flows or assets denominated in the same
currency therefore we are subject to some foreign currency fluctuation risk. Our currency value fluctuations were not material for 2014. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B><I>Our operations and cash flows may be adversely impacted by recent healthcare reform legislation. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">The Patient Protection and Affordable Care Act and Health Care and Education Affordability Reconciliation Act were enacted into law in the U.S. in March 2010. Among other initiatives, this legislation imposes a 2.3% excise tax on
domestic sales of class I, II, and III medical devices beginning in 2013. Substantially all of our products are class I or class II medical devices. In 2014 and 2013 we paid medical device excise tax of approximately $435,926 and $384,438,
respectively. As approximately 84% of our 2014 sales were derived in the U.S. we cannot predict if any additional regulations will be implemented at the federal or state level, or the effect of any future legislation or regulation in the U.S. or
internationally. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Our operations may experience higher costs to produce our products as a result of changes in prices
for oil, gasoline, and other commodities. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We use some plastics and other petroleum-based materials along with
precious metals contained in electronic components as raw materials in many of our products. Prices of oil and gasoline also significantly affect our costs for freight and utilities. Oil, gasoline and precious metal prices are volatile and may
increase, resulting in higher costs to produce and distribute our products. Due to the highly competitive nature of the healthcare industry and the cost-containment efforts of our customers we may be unable to pass along cost increases through
higher prices. If we are unable to fully recover these costs through price increases or offset through other cost reductions, our results of operations could be materially and adversely affected. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We have historically done a substantial amount of business with seven of our top ten customers, who are also major distributors of
our product, which as a group have produced substantial revenues for our Company. Loss of business from a major customer will likely materially and adversely affect our business. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We manufacture the majority of our products on our premises in Clearwater, Florida. Labor-intensive sub-assemblies and labor-intensive
products may be out-sourced to our specification. Although we sell through distributors, we market our products through national trade journal advertising, direct mail, distributor sales representatives and trade shows, under the Bovie name, the
Bovie/Aaron name and private label. Major distributors include Cardinal Health, Independent Medical Co-Op Inc. (IMCO), McKesson Medical Surgical, Inc., Medline, National Distribution and Contracting Inc. (NDC), Owens &amp; Minor, and Physician Sales
&amp; Service (PSS) now a division of McKesson. If any of these distributor relationships are terminated or not replaced, our revenue from the territories served by these distributors could be adversely affected. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are also dependent on OEM customers who have no legal obligation to purchase products from us. Should such customers fail to give us
purchase orders for the product after development, our future business and value of related assets could be negatively affected. Furthermore, no assurance can be given that such customers will give sufficient high priority to our products. Finally,
disagreements or disputes may arise between us and our customers, which could adversely affect production and sales of our products. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We rely on certain suppliers and manufacturers for raw materials and other products
and are vulnerable to fluctuations in the availability and price of such products and services. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Fluctuations in the
price, availability, and quality of the raw materials we use in our manufacturing could have a negative effect on our cost of sales and our ability to meet the demands of our customers. Inability to meet the demands of our customers could result in
the loss of future sales. In addition, the costs to manufacture our products depend in part on the market prices of the raw materials used to produce them. We may not be able to pass along to our customers all or a portion of our higher costs of raw
materials due to competitive and marketing pressures, which could decrease our earnings and profitability. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We also have
collaborative arrangements with four key foreign suppliers under which we request the development of certain items and components and we purchase them pursuant to purchase orders. Our purchase order commitments are never more than one year in
duration and are supported by our sales forecasts. The majority of our raw materials are purchased from sole-source suppliers. While we believe we could ultimately procure other sources for these components, should we experience any significant
disruptions in this key supply chain, there are no assurances that we could do so in a timely manner which could render us unable to meet the demands of our customers, resulting in a material and adverse effect on our business and operating results.
Over the past few years we have expanded the use of our Bulgarian supplier who manufactures a substantial number of our generator and accessory components. We anticipate expanding this relationship further to include manufacturing a large number of
our J-Plasma components. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>If we are unable to protect our patents or other proprietary rights, or if we infringe on the
patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We own 23 patents and 9 registered trademarks in the U.S. and have had 13 patents issued outside the U.S.&nbsp;with some of our early
patents nearing the expiration of their patent term. Of those 23 patents, 15 are related to J-Plasma, with 8 issued and 7 pending. We also have several U.S. and international patent applications pending for various new products. We intend to
continue to seek legal protection, primarily through patents, for our proprietary technology. Seeking patent protection is a lengthy and costly process, and there can be no assurance that patents will be issued from any pending applications, or that
any claims allowed from existing or pending patents will be sufficiently broad or strong to protect our proprietary technology. There is also no guarantee that any patents we hold will not be challenged, invalidated or circumvented, or that the
patent rights granted will provide competitive advantages to us. Our competitors have developed and may continue to develop and obtain patents for technologies that are similar or superior to our technologies. In addition, the laws of foreign
jurisdictions in which we develop, manufacture or sell our products may not protect our intellectual property rights to the same extent as do the laws of the United States. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Adverse outcomes in current or future legal disputes regarding patent and other intellectual property rights could result in the loss of
our intellectual property rights, subject us to significant liabilities to third parties, require us to seek licenses from third parties on terms that may not be reasonable or favorable to us, prevent us from manufacturing, importing or selling our
products, or compel us to redesign our products to avoid infringing third parties&#146; intellectual property. As a result, our product offerings may be delayed, and we may be unable to meet customers&#146; requirements in a timely manner.
Regardless of the merit of any related legal proceeding, we have incurred in the past and may be required to incur in the future substantial costs to prosecute, enforce or defend our intellectual property rights. Even in the absence of infringement
by our products of third parties&#146; intellectual property rights, or litigation related to trade secrets, we have elected in the past and may in the future elect to enter into settlements to avoid the costs and risks of protracted litigation and
the diversion of resources and management&#146;s attention. However, if the terms of settlements entered into with certain of our competitors are not observed or enforced, we may suffer further costs and risks. Any of these circumstances could have
a material adverse effect on our business, financial condition and resources or results of operations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our ability to
develop intellectual property depends in large part on hiring, retaining and motivating highly qualified design and engineering staff with the knowledge and technical competence to advance our technology
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
and productivity goals. To protect our trade secrets and proprietary information, generally we have entered into confidentiality agreements with our employees, as well as with consultants and
other parties. If these agreements prove inadequate or are breached, our remedies may not be sufficient to cover our losses. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Our manufacturing facilities are located in Clearwater, Florida and could be affected due to multiple risks from fire, hurricanes,
physical changes in the planet due to climate change, and similar phenomena. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our manufacturing facilities are located
in Clearwater, Florida and could be affected by multiple weather risks, most notably hurricanes. Although we carry property and casualty insurance and business interruption insurance, future possible disruptions of operations or damage to property,
plant and equipment due to hurricanes or other weather risks could result in impaired production and affect our ability to meet our commitments to our customers and impair important business relationships, the loss of which could adversely affect
our operations and profitability. We do however maintain a backup generator at our Clearwater facility and a disaster recovery plan is in place to help mitigate this risk. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We do not produce hazardous materials or emissions that would adversely impact the environment.&nbsp;We do however, have air
conditioning units and consume electricity which could be impacted by climate change in the form of increased rates. However, we do not believe the increase in expense from any rate increases, as a percentage of sales, would be material in the near
term. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We have been and may in the future become subject to litigation proceedings that could materially and adversely
affect our business. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Other Litigation </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition to the litigation risks and proceedings mentioned below, we have recently been involved and may in the future become subject
to legal claims or proceedings related to securities, employment, customer or third party contracts, environmental regulations, or other matters. The costs involved in defending these claims have been substantial, which have had an adverse effect on
our profitability. In addition, if other claims are asserted against us, we may be required to defend against such&nbsp;claims, or deem it necessary or advisable to initiate a legal proceeding to protect our rights, the expense and distraction of
such a claim or proceeding, whether or not resolved in our favor, could materially and adversely affect our business, financial condition and operating results. Further, if a claim or proceeding were resolved against us or if we were to settle any
such dispute, we may be required to pay damages and costs or refrain from certain activities, any of which could have a material adverse impact on our business, financial condition and operating results. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Intellectual Property Litigation or Trade Secrets </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have in the past, experienced certain allegations of infringement of intellectual property rights and use of trade secrets and may
receive other such claims, with or without merit, in the future. Previously, claims of infringement of intellectual property rights have sometimes evolved into litigation against us, and they may continue to do so in the future. It is inherently
difficult to assess the outcome of litigation. Although we believe we have had adequate defenses to these claims and that the outcome of the litigation will not have a material adverse impact on our business, financial condition, or results of
operations, there can be no assurances that we will prevail. Any such litigation could result in substantial cost to us, significantly reduce our cash resources, and create a diversion of the efforts of our technical and management personnel, which
could have a material and adverse effect on our business, financial condition and operating results. If we are unable to successfully defend against such claims, we could be prohibited from future sales of the allegedly infringing product or
products, which could materially and adversely affect our future growth. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Product Liability Litigation </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Although we carry liability insurance, due to the nature of our products and their use by professionals, we may, from time to time, be
subject to litigation from persons who sustain injury during medical procedures in </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
hospitals, physician&#146;s offices or in clinics and defending such litigation is expensive, disruptive, time consuming and could adversely affect our business. We currently maintain product
liability insurance with combined coverage limits of $10 million on a claims-made basis. There is no assurance that this coverage will be adequate to protect us from any possible liabilities (individually or in the aggregate) we might incur in
connection with the sale or testing of our products. In addition, we may need increased product liability coverage as additional products are commercialized. This insurance is expensive and in the future may not be available on acceptable terms, if
at all. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Our business is subject to the potential for defects or failures associated with our products which could lead
to recalls or safety alerts and negative publicity. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Manufacturing flaws, component failures, design defects,
off-label uses or inadequate disclosure of product-related information could result in an unsafe condition or the injury or death of a patient. These problems could lead to a recall of, or issuance of a safety alert relating to, our products and
result in significant costs and negative publicity. Due to the strong name recognition of our brands, an adverse event involving one of our products could result in reduced market acceptance and demand for all products within that brand, and could
harm our reputation and our ability to market our products in the future. In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the suspension or delay of our
current regulatory reviews of our applications for new product approvals. We also may undertake voluntarily to recall products or temporarily shut down certain production lines based on internal safety and quality monitoring and testing data. Any of
the foregoing problems could disrupt our business and have a material adverse effect on our business, results of operations, financial condition and cash flows. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We have incurred and may in the future incur impairments to our long-lived assets. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We review our long-lived assets, including intangible assets, for impairment annually or more frequently if events or changes in
circumstances indicate that the carrying amount of these assets may not be recoverable. Additionally, if in any period our stock price decreases to the point where our fair value, as determined by our market capitalization, is less than the book
value of our assets, this could also indicate a potential impairment and we may be required to record an impairment charge in that period which could adversely affect our results of operations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our valuation methodology for assessing impairment requires management to make judgments and assumptions based on historical experience
and to rely heavily on projections of future operating performance. We operate in highly competitive environments and projections of future operating results and cash flows may vary significantly from actual results. Additionally, if our analysis
indicates potential impairment to a long-lived intangible asset, we may be required to record additional charges to earnings in our financial statements, which could negatively impact our results of operations. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Risks Related to Our Stock and this Offering </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>The market price of our stock has been and may continue to be highly volatile. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our common stock is listed on the NYSE MKT under the ticker symbol &#147;BVX.&#148; The market price of our stock has been and may
continue to be highly volatile, and announcements by us or by third parties may have a significant impact on our stock price. These announcements may include: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">our listing status on the NYSE MKT; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">our operating results falling below the expectations of public market analysts and investors; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">developments in our relationships with or developments affecting our major customers; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">negative regulatory action or regulatory non-approval with respect to our new products; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">government regulation, governmental investigations, or audits related to us or to our products; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">developments related to our patents or other proprietary rights or those of our competitors; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">changes in the position of securities analysts with respect to our stock. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">The stock market has from time to time experienced extreme price and volume fluctuations, which have particularly affected the market prices for the medical technology sector companies, and which have often been unrelated to their
operating performance. These broad market fluctuations may adversely affect the market price of our common stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Historically, when the market price of a stock has been volatile, holders of that stock have often instituted securities class action
litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition, future sales by existing stockholders, warrant holders receiving shares upon the exercise of warrants, or any
new stockholders receiving our shares in any financing transaction may lower the price of our common stock, which could result in losses to our stockholders. Future sales of substantial amounts of common stock in the public market, or the
possibility of such sales occurring, could adversely affect prevailing market prices for our common stock or our future ability to raise capital through an offering of equity securities. Substantially all of our common stock is freely tradable in
the public market without restriction under the Securities Act, unless these shares are held by our &#147;affiliates&#148;, as that term is defined in Rule 144 under the Securities Act. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We have no present intention to pay dividends on our common stock and, even if we change that policy, we may be unable to pay
dividends on our common stock. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We currently do not anticipate paying any dividends on our common stock in the
foreseeable future. We currently intend to retain future earnings, if any, to finance operations and invest in our business. Any declaration and payment of future dividends to holders of our common stock will be at the discretion of our board of
directors and will depend on many factors, including our financial condition, earnings, capital requirements, level of indebtedness, statutory and contractual restrictions applying to the payment of dividends and other considerations that our board
of directors deems relevant. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If we change that policy and commence paying dividends, we will not be obligated to continue
paying those dividends and our stockholders will not be guaranteed, or have contractual or other rights, to receive dividends. If we&nbsp;commence paying dividends in the future, our board of directors may decide, in its discretion, at any time, to
decrease the amount of dividends, otherwise modify or repeal the dividend policy or discontinue entirely the payment of dividends. Under the Delaware law, our board of directors may not authorize the payment of a dividend unless it is either paid
out of our statutory surplus. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>The low trading volume of our common stock may adversely affect the price of our shares
and their liquidity. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Although our common stock is listed on the NYSE MKT exchange, our common stock has experienced
low trading volume. Limited trading volume may subject our common stock to greater price volatility and may make it difficult for investors to sell shares at a price that is attractive to them. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>We may in the future seek to raise funds through equity offerings, which could have a dilutive effect on our common stock.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In the future we may determine to raise capital through offerings of our common stock, securities convertible into
our common stock or rights to acquire these securities or our common stock. The result of sales of such securities, the exercise of warrants issued in connection with any such offering or the triggering of anti-dilution
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
provisions in such securities would ultimately be dilutive to our common stock by increasing the number of shares outstanding. We cannot predict the effect this dilution may have on the price of
our common stock. In addition, the shares of preferred stock may have rights which are senior or superior to those of the common stock, such as rights relating to voting, the payment of dividends, redemption or liquidation. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Exercise of warrants and options issued by us will dilute the ownership interest of existing stockholders. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As of April 13, 2015, the warrants issued by us in April 2010 were exercisable for up to approximately 530,001 shares of our common
stock, representing approximately 2.3% of our then outstanding common stock. These warrants expire on April 18, 2015. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As of
April 13, 2015, the warrants issued by us in December 2013 were exercisable for up to approximately 386,875 shares of our common stock, representing approximately 1.7% of our then outstanding common stock. These warrants expire on June 13, 2019.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As of April 13, 2015, our outstanding stock options to our employees, officers, directors and consultants amounted to
approximately 2,899,189 shares of our common stock, representing approximately 12.4% of our then outstanding common stock.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The exercise of some or all of our warrants and stock options will dilute the ownership interests of existing stockholders. Any sales in
the public market of the common stock issuable upon such conversion or exercise could adversely affect prevailing market prices of our common stock. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This prospectus contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities
Act regarding our business, financial condition, results of operations and prospects. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify
forward-looking statements. However, these are not the exclusive means of identifying forward-looking statements. Although forward-looking statements contained in this prospectus reflect our good faith judgment, such statements can only be based on
facts and factors currently known to us. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual outcomes may differ materially from the results and outcomes discussed in the forward-looking statements.
Further information about the risks and uncertainties that may impact us are described or incorporated by reference in &#147;Risk Factors&#148; above. You should read that section carefully. You should not place undue reliance on forward-looking
statements, which speak only as of the date of this prospectus. We undertake no obligation to update publicly any forward-looking statements in order to reflect any event or circumstance occurring after the date of this prospectus or currently
unknown facts or conditions or the occurrence of unanticipated events. In addition, our past results are not necessarily indicative of future results, thus, we cannot guarantee future results, levels of activity, performance or achievements.
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">14
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_4"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The shares of common stock to be offered and sold pursuant to this prospectus will be offered and sold by the selling stockholders or
their transferees. We will not receive any proceeds from the sale of the shares of common stock by the selling stockholders. We will, however, receive the proceeds of any cash exercises of warrants which, if received, would be used to fund clinical
and commercial development activities and for general corporate purposes. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">15
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_5"></A>SELLING STOCKHOLDERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The shares of common stock being offered by the selling stockholders are those that are issuable to the selling
stockholders upon conversion of the shares of Series B Convertible Preferred Stock and upon the exercise of five and one-half-year warrants issued to them. For additional information regarding the issuance of the shares of common stock and the
warrants, see &#147;About this Offering&#148; above. We are registering the shares of common stock in order to permit the selling stockholders to offer the shares for resale from time to time. Except for the ownership of the shares of Series B
Convertible Preferred Stock issued pursuant to the exchange transaction mentioned above, the issuance of the warrants pursuant to a Securities Purchase Agreement and&nbsp;the fact that Ian Sheffield, a director of the Company, is a director nominee
of the selling stockholders that own the shares of Series B Convertible Preferred Stock the selling stockholders have not had any material relationship with us within the past three years. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The table below lists the selling stockholders and other information regarding the beneficial ownership (as determined
under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder) of the shares of common stock held by each of the selling stockholders. The second column lists the number of shares of common stock
beneficially owned by the selling stockholders, based on their respective ownership of shares of common stock, as of April 13, 2015. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The third column lists the shares of common stock being offered by this prospectus by the selling stockholders.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In accordance with the terms of a registration rights agreement with the holders of the shares of common
stock, this prospectus generally covers the resale of the shares of common stock which are issuable upon conversion of the shares of Preferred Stock that have been issued to the selling stockholders. The fourth column assumes the sale of all of the
shares offered by the selling stockholders pursuant to this prospectus. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The selling stockholders may sell
all, some or none of their shares in this offering. See &#147;Plan of Distribution.&#148; </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Beneficial</B></FONT><br><FONT COLOR="#50748a"><B>Ownership&nbsp;Before&nbsp;Offering</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Total&nbsp;Shares</B></FONT><br><FONT COLOR="#50748a"><B>Offered</B></FONT><br><FONT COLOR="#50748a"><B>By
Selling</B></FONT><br><FONT COLOR="#50748a"><B>Stockholder</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Beneficial</B></FONT><br><FONT COLOR="#50748a"><B>Ownership&nbsp;After&nbsp;Offering</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Selling Stockholder</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>&nbsp;&nbsp;&nbsp;&nbsp;Shares&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>&nbsp;&nbsp;&nbsp;&nbsp;Percent&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Shares(1)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Percent(1)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Biomedical Value Fund, L.P.(2)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">3,390,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">12.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">3,390,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Biomedical Institutional Value Fund, L.P.(2)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">871,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(4)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">3.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">871,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(4)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Biomedical Offshore Value Fund, Ltd.(2)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1,896,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(5)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">7.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1,896,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(5)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">WS Investments II, LLC(2)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">128,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(6)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">128,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(6)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Class D Series of GEF-PS, L.P.(2)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">889,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(7)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">3.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">889,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(7)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Gilford Securities Incorporated(8)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">262,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(9)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">262,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(9)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">David S. Kaplan</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">64,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(10)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">64,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(10)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">John Cierski</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(11)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">(11)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #50748a;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Less than 1% of the outstanding Shares of common stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Assumes that all the shares of the selling stockholders covered by this prospectus are sold, and that the selling stockholders do not acquire any additional shares of common stock before the
completion of this offering. However, as each selling stockholder can offer all, some or none of its common stock, no definitive estimate can be given as to the number of shares that any selling stockholder will ultimately offer or sell under this
prospectus. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Great Point Partners, LLC (&#147;Great Point&#148;) is the investment manager of each of
Biomedical Institutional Value Fund,&nbsp;L.P., Biomedical Offshore Value Fund,&nbsp;Ltd., Biomedical Value Fund,&nbsp;L.P., Class&nbsp;D Series of GEF-PS,&nbsp;L.P. and WS Investments II,&nbsp;LLC (collectively, the &#147;Great Point Selling
Stockholders&#148;), and has the power to vote or dispose of the shares listed above. Each of Dr. Jeffrey R. Jay, M.D. (&#147;Dr. Jay&#148;), as </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">16
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">
senior managing member of Great Point, and Mr. David Kroin (&#147;Mr. Kroin&#148;), as special managing member of Great Point, has voting and investment power with respect to the shares owned by
each of the Great Point Selling Stockholders. Each of Great Point, Dr. Jay and Mr.&nbsp;Kroin disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interest therein. The address for the Great Point Selling
Stockholders is 165 Mason Street, 3rd&nbsp;Floor, Greenwich, CT 06830. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 3,390,348 shares of common stock issuable upon the conversion of Series B preferred stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 871,890 shares of common stock issuable upon the conversion of Series B preferred stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 1,896,640 shares of common stock issuable upon the conversion of Series B preferred stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 128,066 shares of common stock issuable upon the conversion of Series B preferred stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 889,334 shares of common stock issuable upon the conversion of Series B preferred stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Robert A. Maley, President of Gilford Securities Incorporated, has voting and investment control over the shares held by the selling stockholder. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 262,500 shares issuable upon the exercise of warrants. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 64,375 shares issuable upon the exercise of warrants which were assigned to the Selling Stockholder by Gilford Securities Incorporated. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Consists of 60,000 shares issuable upon the exercise of warrants which were assigned to the Selling Stockholder by Gilford Securities Incorporated. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">17
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_6"></A>PLAN OF DISTRIBUTION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are registering the shares of common stock that are issuable upon conversion of the shares of Series B Preferred
Stock, which have been issued to the selling stockholders, to permit the resale of these shares of common stock by the holders thereof from time to time after the date of this prospectus. We are also registering the shares of common stock that are
issuable upon the exercise of warrants which have been issued to the selling stockholders. We will not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock issuable upon the conversion of the Series B
Preferred Stock. We will, however, receive the proceeds of any cash exercises of warrants. We will bear all fees and expenses incident to our obligation to register the shares of common stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Each Selling Stockholder (the &#147;<B>Selling Stockholders</B>&#148;) of the securities and any of their pledgees,
assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded or in private
transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;
</FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">an exchange distribution in accordance with the rules of the applicable exchange; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">privately negotiated transactions; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">a combination of any such methods of sale; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">any other method permitted pursuant to applicable law. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">The Selling Stockholders may also sell securities under Rule 144 under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), if available, rather than under this prospectus. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales.
Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to
this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging
transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Shareholders may also, to the extent permitted under Rule 105
of Regulation M, sell shares of their common stock short and deliver these securities to close out their short positions, or loan or pledge shares of their common stock to broker-dealers that in turn may sell these securities. The Selling
Stockholders may also enter into option or other transactions with </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">18
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by
this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to
be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be
deemed to be underwriting commissions or discounts under the Securities Act. In no event shall any broker-dealer receive fees, commissions and markups, other than in connection with the closing of the securities purchase agreements by and between
various Selling Stockholders and the Company, which, in the aggregate, would exceed eight percent (8%). </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities however, a Selling Stockholder will pay all underwriting discounts and commissions, if any. The Company has agreed to
indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Because Selling Stockholders may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act, they
will be subject to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold
under Rule 144 rather than under this prospectus. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The Company agreed to keep a Registration Statement
effective until the later of (i) March 17, 2018, (ii) the date on which the Registrable Securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144,
without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (iii) the date on which all of the Registrable Securities have been sold
pursuant to a Registration Statement or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities&nbsp;will be sold only through registered or licensed brokers or dealers if required under applicable state
securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement
is available and is complied with. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Under applicable rules and regulations under the Exchange Act, any person
engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the
distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of securities of the
common stock by the Selling Stockholders or any other person. The Company will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior
to the time of the sale (including by compliance with Rule 172 under the Securities Act). </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">19
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_7"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The validity of the issuance of securities offered hereby will be passed upon for us by Ruskin Moscou Faltischek, P.C.,
of Uniondale, New York. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_8"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The consolidated financial statements incorporated in this prospectus by reference from Bovie Medical Corporation&#146;s
Annual Report on Form l0-K for the year ended December 31, 2014 have been audited by Frazier and Deeter, LLC, independent auditors, as stated in their report, which is incorporated herein by reference, and have been so incorporated in reliance upon
the report of such firm given upon their authority as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_9">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We file annual, quarterly and current reports, proxy statements
and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at www.sec.gov. You may also read and copy any document we file at the SEC&#146;s public reference room at 100 F Street,
N.E., Washington, D.C. 205409. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">20
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc282794_10"></A>INCORPORATION OF CERTAIN INFORMATION BY
REFERENCE </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The SEC allows us to incorporate by reference the information we file with it, which means
that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information in documents that we file later with the SEC will
automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c) 14 or 15(d) of the Securities
Exchange Act of 1934, as amended, until this offering is completed and all securities are sold: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on March&nbsp;1, 2015. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Current Report on Form 8-K filed with the SEC on March 31, 2015. </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Current Report on Form 8-K filed with the SEC on March 17, 2015. </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Current Report on Form 8-K filed with the SEC on March 12, 2015. </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Current Report on Form 8-K filed with the SEC on March 11, 2015. </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Our Current Report on Form 8-K filed with the SEC on March 2, 2015. </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#50748a">Description of the Registrant&#146;s Common Stock contained in the Registration Statement on Form 8-A filed with the SEC on November 3, 2003. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Upon request, Bovie will provide, free of charge, to each person to whom a prospectus is delivered, including a
beneficial owner, a copy of any or all information that has been incorporated by reference in the prospectus but not delivered with the prospectus. Any such request may be made orally or in writing to Bovie Medical Corporation, 4 Manhattanville
Road, Suite 106, Purchase, New York 10577, Attention: Peter Donato, CFO, Tel. No.: (727) 803-8593. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">21
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #50748a">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #50748a">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>1,500,000 Shares </B></FONT></P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>BOVIE MEDICAL CORPORATION </B></FONT></P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>Common Stock </B></FONT></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g282794g63m68.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #50748a;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>PROSPECTUS SUPPLEMENT </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #50748a;width:21%">&nbsp;</P></center> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#50748a"><B>Piper Jaffray </B></FONT></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #50748a;width:21%">&nbsp;</P></center> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#50748a"><B>The date of this prospectus supplement is November 10, 2016 </B></FONT></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #50748a">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #50748a">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g282794g31r32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g282794g31r32.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1V<4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0%@:/4         *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #P     $  0/      0 !.$))300F       .
M #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@
M70   *$          0                         !              "A
M    70                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    70    !29VAT;&]N9P   *$    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   %T     4F=H=&QO
M;F<   "A     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    ".$))300,     !,.     0   *    !<   !X   K(   !+R !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !< * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5))))2DDDR2E:ZI=
MEF=0Z_T[!<6/?ZE[?\"R2[^U^8W^VN?S?K3U"\[: ,6L_![_ /.+=K/[+%-B
MY;+DU H?O2TBUL_/8,-B4N*0_1AZI?\ H+UU^11CL-E[Q6P?G.,!963];.EU
M2*2[)=X5@Q_GO:UBY:C!ZAU*W?779D./^%L)#1_URSV_YBV,7ZGY#X=F7BO^
M36 [_IN_\@I_N^#'_.Y+/[L6I]]YO-_,8.&/[^3\_P!UE9]<;R?T6)M'\NP?
M]]K=_P!6GI^N1#P,G&AGYSV/W0/Y3-C?^J6A3]5NCU@;ZC<?&PG\C2QJYCK5
M>#C]1MJPP!36 '@$D->/IM;NW.3\4>5RDPCCEM?%?_H3'S&3G^7B,F3+"B:X
M:XOPX(O=U6LNK;;6[=6\ M<.X*(LSZO468_1\>N[1^W='@'>YH6D#K"H3 $I
M &P"1?=U<<C*$92'"9 $C]TGHR22207K)M>4+)RL?%K]7(L;4R8W.,"2D[)H
M;1]H=8T4QN]2=(/YVY*BBQJ+VU>:ZP>I]4ZP>FXYLJHJ@%XEK=?<^USOS_\
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M_JKJ.F_5G PXLM'VF[]]X$ _\&P>U6ZY?E]_UF3^7^*Y_%SO.;?J<)^G$/\
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M:Z/I]%EF'C7=0K:_,:T%SRT;@?I?V7-G\W\]0\QD)$9$7CU$!+YI?ZPMCD\
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MQ*?64C&[<CFL5Y">9S&&._3&$<ACP_WN'A>;POJ?<XAV==M:=373S\#8]O\
MWU;F'T?IV$V**6[N[W@.=\['>]71PG,*//\ >?\ * @>'R_\UL<H.1%>R8F7
M>7S_ //5&B=))56^I))))2DDDDE*22224I))))2DDDDE/__9.$))300A
M  !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M$P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X
M0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0
M  "< 3L  @    D   "PAVD !     $   "\    Z  .M@0  "<0  ZV!
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C$Q.C S(# P
M.C V.C,Y ')R,3$W-3<R       #H $  P    '__P  H ( !     $   "A
MH , !     $   !=          8! P #     0 &   !&@ %     0   38!
M&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M2$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M"0   +"':0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,3$Z,#,@,# Z,#8Z,SD <G(Q
M,3<U-S(       .@ 0 #     ?__  "@ @ $     0   *&@ P $     0
M %T         !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !
M/@$H  ,    !  (   (!  0    !   !1@("  0    !              /
M     0   \     !_^% &FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
M/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C
M>FMC.60B/SX\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X
M.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P
M,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#$V+3$Q+3 R5#(S
M.C4T.C,U*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP.D-R
M96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C Q-BTQ,2TP
M,U0P,#HP-CHS.2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,38M,3$M,#-4,# Z,#8Z,SDK,#4Z,S \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @
M(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N.2 H
M5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O
M,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!
M;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L
M="(^36EC<F]S;V9T(%=O<F0@+2!396-O;F1A<GD@4')E;&EM:6YA<GD@4')O
M<W!E8W1U<R!3=7!P;&5M96XN1$]#/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F-R
M96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/G)R,3$W-3<R/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T
M/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @
M(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z-S5"14$V,S(R.4$Q138Q,4$X,C-$,C=&,C S0C0Y,48\
M+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$
M/GAM<"YD:60Z-S-"14$V,S(R.4$Q138Q,4$X,C-$,C=&,C S0C0Y,48\+WAM
M<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^>&UP+F1I9#HW,T)%038S,C(Y03%%-C$Q03@R,T0R-T8R,#-"-#DQ
M1CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-S-"
M14$V,S(R.4$Q138Q,4$X,C-$,C=&,C S0C0Y,48\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,38M,3$M,#-4
M,# Z,#8Z,S8K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW-$)%038S,C(Y03%%-C$Q03@R
M,T0R-T8R,#-"-#DQ1CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C Q-BTQ,2TP,U0P,#HP-CHS.2LP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE
M=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-S5"
M14$V,S(R.4$Q138Q,4$X,C-$,C=&,C S0C0Y,48\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,38M,3$M,#-4
M,# Z,#8Z,SDK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O
M;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E
M9CII;G-T86YC94E$/GAM<"YI:60Z-S1"14$V,S(R.4$Q138Q,4$X,C-$,C=&
M,C S0C0Y,48\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z-S-"14$V,S(R.4$Q138Q,4$X,C-$,C=&
M,C S0C0Y,48\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HW,T)%038S,C(Y03%%-C$Q
M03@R,T0R-T8R,#-"-#DQ1CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO
M<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" != * # 1$  A$! Q$!_\0 '@   @$% 0$!            " D
M P0&!PH% @'_Q  [$  !! $"!0,"! 4# @<!   " 0,$!08'$0 ($A,A"2(Q
M%$$5(S)1)$)A<8$6D:$S4A<8)30U0\'A_\0 '0$  @$% 0$
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M]CB629]J>I24=96T42F0"-))WQ)M+ *FX!V5/4T]/6QH5'!BU]>Q';"-&BL
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M5%EU.RI>$7QMLG&XVR&+4W>&XW"-MT&GJ6%$(R1]P%:'!5C$P8'<,%9%S\$
M8$=YDGT']-UBM4P*U&KKM55DJ,RAHZ.5UGW HM0AC92,[3&Q'RI&WH<<6UKR
MS!-/,VTYQ)6ZIC.WXQ7]\R:E-?K&8PLE5QT)O^$%X17O/"X"$WNTB$)N$1"N
M>B*2[Z@H;]7R.6MO-+3E%,23 _\ >;;*LCLOPI&U><J2!@/6;N7<--::OVBM
M(0QP17Y$EJKBLA-0WK!1)3)'6P2*BLQ9G<N%(QL"J#N;%Z:W*!%K(,;F'U/K
MS&4['-W *V:WL,"N0.DKU]D7![4V6 _PR$TH-1?<B(;SJ<+OWL[ESW"HETA9
MCNIHI!%=)%./7D0@K"5EIT8;'R7"RL"VW<<J.G6^E+L8EFHU[DZM7?<JV!'M
M,,BX^UIE#;YS]K72T\GJ'#QEJ=,+XR,8!SG,U=ON:+F'2EQ1Q;"KK;@,#PFO
M8419D2EFI%EV2$B!UD_( WC>4$0:]@>HE[*DA3[7V&FT)HDW6J'IR55.;A<W
M8[@L>"T0]CS *JNH+(H?)]P'2_?4#JNZ]WNY]!:+#.L]+27&2PVV$"&-3*K[
M)YBU1'2,[NT;$1EV4A,)+@@]'KS25S7*/R0XQHYCC@,7F<$W27=@R  _+64V
MEEDDIQ?S4)7E1(_<%P%1J1VA3W(B"+0DL_<7NJU_K@'@M\@JHQ[ %2%7IZ-2
M$^V+% %RWIMD@$KYPR/=RGA[,?3_ $6BK3((:V\H:&>7W[G>H(J[FX]0U@42
M,S#:9@%1B%<9 (-\H/(Y9<S,29F62Y<>'Z?U=@Y6DY A19=G;2(P@LT6"==:
MCQ&=S6.KX1I/\0VZA,"K2<%_N;W8_P"BJLV2W4/WMR:F217:3THZ-IDS$=KT
MLPJ,@JY3U%&#MW@[MJU]B_IUF[L^OJO4EW6BTY!5R4WH1P;IJYH=@G(DI:^D
M>F&[?&#M?W*79#M&2%UAYC=%>4[%K/1'E&KJZ5F+[91<LU*$QGI EBT;3SDF
M98HY^*9 &[O0V#OT%>OEU01M(RCW2NBM3=RKG'J?7<SBUG8U/1QK30BI1,H(
M@M#44\M*N GZQH?68>T$8!Z,FO.ZFA.R5FG[<]GJ>-K\JO'67)WK9S0/)&9!
M,LUVIZNGK)BS-^K%288L^."HH<@/)+?:I9)"UWUH8G%C<2R_',:J[A"?GY5<
MF\L@L@M^I]J<W%:>(9$/O"06#XI)$1BL LKZ]W>Z%):Z*31VFVC"^FM)4R1J
MQ6&&(*IIPL],6616 7>LS,%#$D[E(L?II[ 774UQB[F]P1*\0JFN-KHYS$7J
MZJ=I9!<9)J*N1GBF60MZ$M,(]Q7:N%8'H:%&FA!!1&P;!$';=>E/THFWWW39
M/CQONOQPHI."0YR#SGQX\\#^/72H;=@;P%X YX'CS_+'CJT=I:M^0DUV&RY)
M;,D!XFE)U$WZMD/=.GR7ROVW3C[^M4!?329EC_>3 ((_+/C(XX_F#U;_ &E.
MS^K) K2KG8^<$?/D?GUZ";]" !;J([^13?PB>WSXW3;Y1?OQ\?V<\<<DG/\
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MD!R7(,B-%?DJBO/N"ON<(_'&GWB[5E]N%1<:Q\SU,LDKGV;278G"X5 H'
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ME:G:MY/J#3:KRZ.LSFVD7EY63<=CW<VLERE%'F:R:[;P".$C;71&9D#VX0=
MMB\@"G#"Z.[ZG3NFJ>SSZ?%34T:NM/4K<3"JML58V:,6Z96*E 6RSASD@@'"
MIAW&^E*HUAK.Y:DM6M#9J:]N'N5 ]C2XEMS2&7TZB>\0,NX2,JB*.$*N,!G&
MXK=YS.7/3/EENL-P?&<DO<HSF=&*UR*3:R8H-1*A.MF*2PF4Z&7),Q$6)TN=
M11HKH$;BCU<'+M'K#4NMTN5SNRQ1VR%S3T8C2GW?='9(P9HHJ>5ML3'!]/8<
MY8[B,J=]0W:W2';"6QVFU35=UOXA6MN)J9YH%6EB1XHF2,RS1*TDY#8$K.$
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MOESX VT-)4E<^!OVC\#D= 'J'ZP]!'8F1]---[BS,45J)<Y+9Q*.#U;["X,
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MYMGKTAY75R/+;)Z'CS/62EWVI-T;-<T(J6XL53$I[I1$0?WW&JOW;OMQ')!
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G<3J=3B=3J<3J=3B=3J<3J=3B=3J<3J=3B=3J<3J=3B=3J<3J=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g282794g63m68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g282794g63m68.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1BD4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #P     $  0/      0 !.$))300F       .
M #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@
MV@   MX          0                         !              +>
M    V@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    V@    !29VAT;&]N9P   MX    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   -H     4F=H=&QO
M;F<   +>     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,      X6     0   *     P   !X   6@    WZ !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P * # 2(
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z  ]"0   "<0 #T)    )Q!!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C$Q.C S(# P.C$P.C$Y ')R,3$W
M-3<R       #H $  P    '__P  H ( !     $   +>H , !     $   #:
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0              2
M  $   !(     3A"24T#_0      "           _^$!2$U- "H    (  @!
M$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M 0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,38Z,3$Z,#,@,# Z,3 Z,3D <G(Q,3<U-S(       .@
M 0 #     ?__  "@ @ $     0   MZ@ P $     0   -H         !@$#
M  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (
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M<Y33,U1B='63L;*TT>,D-%5D@9&2H;/44X*#HL+2XO_:  P# 0 "$0,1 #\
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ME*4WYNML._2T?D4E666\84TJFJ_&C;U.>-A\-]OT\8# /5T]$C=R<'I4=%&
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M1&,I]Q6*<AS*O2[A*7=X86I*';JUQ ,]VFDG9L898(':G@B)\R 4EF'I\_\
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MV!58YP<XN47>-Y&T>$@==2N8Z+))K.D-#4%N5M*X5-A/%3)3DR8V,A<Q99?
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MAJ[[N%_9/M>:N6J&)R9^E/4*D?S73 Y9D7D.7;OW.-'FW=Q6^2"V6E?:/:Q
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M&\1^VYPVX0MK*X_:<AX"VDA*CY+8\^07;-B2(CN$8(&7:9QTHN,"+]M"BXN
M1#Q)"T)6X!E6,9Z6]YW1>[\<7&NDDA#<EI8P(:52#D$0QX5F'H\G-Q^5HPMU
MDMEK[T=,J2$%3.Y,DY!\QU'R54X&53BIQY:QAYFZQJUCY#0P,FB35^)UZX0\
M\/*FCI ?W9;:KHVZ&,QC3F(&8(:I>N:J36V[;$60*MV@'-EBQ&)'+:VK6QU<
MT5LD9.'S7M1 **>0H();A "Y^<0=>IE$I@>)I86Z3L5UH7*".2N ;E[P@/9B
7 IJI8Z24A?H-\U#&4ZBR!)%YJ VO_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
